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 ABSTRACT   
 
Hypoxia Regulated Pathways in Urological Malignancies 
Philip John Stuart Charlesworth 
 
 
 
Introduction:       Kidney Cancer accounts for approximately 2% of all new cancer diagnoses in 
the  UK  each  year.  Patient  survival  has  improved  over  the  past  few  decades;  however  the 
mechanisms of this are yet to be fully elucidated. Hypoxia inducible factor isoforms, HIF-1 and 
HIF-2,  are  constitutively  expressed  in  many  clear-c e l l   R C C s   d u e   t o   l o s s   o f   p V H L   t u m o u r  
suppressor function within the tumour. In vitro, HIF-1 and HIF-2 regulate a differential set of 
target genes, although their expression in primary ccRCC clinical samples and their effects on 
patient prognosis has yet to be fully understood.  
 
Methods:      In  this  thesis  analysis  has  been  performed  on  all  Nephrectomies  performed  at 
Oxford Radcliffe Hospitals for Renal Cell Carcinoma (RCC) from 1983 to 2007. Data extracted 
from Charlesworth Research Uro-Oncology Database, CRUD©, provided long-term survival 
data, maximal tumour diameter, Fuhrman grade, T-Staging and patient age. A subset of RCCs 
from this series (170 consecutive clear cell renal tumours from 1983 to 1999) were analysed 
within a tissue microarray and expression of HIF-1 and HIF-2, together with seven primary 
target  genes  (BNIP3,  CAIX,  CyclinD1,  GLUT1,  LDH5,  Oct-4  and  VEGF)  was  assessed. 
Comparison  was  made  with  tumour  angiogenesis  (CD31),  tumour  stage,  Fuhrman  grade, 
maximum tumour diameter and patient survival. Further work in this thesis analysed a series of 
paired VHL (functional and non-functional) ccRCC cell lines, assessing for hypoxic differential 
MicroRNA expression.   
 
Results:   Analysis of 664 RCCs demonstrated a clear change in kidney cancer specific survival 
over the past 24 years, with 5-year survival improving from 42% (1983-1986) to 73% (1999-
2002). The incidence of RCC has increased 10 fold and has a significant association with 4-year 
survival. There was no significant change in operative mortality, patient age, Fuhrman grade, 
Pathological T-Stage or mean tumour size. However, there was a 5-fold increase in tumours 
<6cm, corresponding to an equal fold decrease in tumours 6-8cm,  and no change in tumours 
>8cm. Tumour size >8cm was a significant prognostic marker. HIF-1 and HIF-2 showed no 
correlation and individually, neither HIF-1 nor HIF-2 expression had any prognostic utility; 
however  a  significant  time-dependent deterioration  of  HIF-1 and HIF-2  antigenicity  within 
paraffin blocks was identified. Angiogenesis (VVI CD31) had a strong negative correlation with 
Fuhrman grade and maximal tumour diameter and had prognostic significance, with high levels 
associated  with  good  overall  survival.  Results  from  microRNA  expression  arrays  found  a 
specific  microRNA  (MiR-23a)  that  was  differentially  expressed  depending  upon  VHL 
functionality and hypoxic conditions. Furthermore microRNA-23a was up-regulated in cells that 
expressed both HIF isoforms, and down-regulated in cells that only expressed HIF-2. 
 
Conclusions:      Outcome following Nephrectomy for Renal Cell Carcinoma has dramatically 
improved over the past 24 years. Increasing incidence and decreasing tumour size at operation 
combined with the lack of statistical variation in Fuhrman grade, suggests that earlier detection 
of tumours offers subsequent curative treatment by Nephrectomy. Furthermore, stable incidence 
rates of tumours >8cm potentially represent alternative tumour biology, which grow rapidly, 
avoiding early detection and curative treatment. Although neither HIF isoform nor the seven 
HIF target genes was found to influence disease prognosis, the discovery of HIF antigenicity 
deterioration with time, is a very important finding and casts into doubt previous literature about 
HIF-1 immunostaining in human cancers. The prognostic significance of CD31
+ angiogenesis 
appears initially counterintuitive, however, CD31
+ endothelial cells may represent functional 
vessels which protect the tumour from sustained periods of ischaemia, unlike the low VVI 
group, from which hypoxia death-resistant  clones  could  arise  facilitating  tumour  metastasis. 
This  could  be  very  important  when  considering  the  effects  of  biologically  targeted  anti-
angiogenic therapies.  Furthermore, the negative correlation with angiogenesis (CD31+) and 
Fuhrman grade suggests that vessel functionality and tumour aggressiveness may change with 
tumour size. The finding of a specific microRNA that appears to have VHL and HIF dependent 
expression extends our understanding of the hypoxic pathway and opens the possibility of 
further development of novel targeted therapies.  
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Adenosine Triphosphate, ATP – universal form of energy used by living 
cells 
 
Angiopoetin2, Ang2 – pro-angiogenic polypeptide 
 
Basic Fibroblast Growth Factor, bFGF – growth factor present in basement 
membranes and in the subendothelial extracellular matrix of blood vessels, 
and when activated can mediate the formation of new blood vessels 
 
BCL2/adenovirus E1B 19kDa interacting protein 3, BNIP3 – human gene 
involved in cell apoptosis and autophagy 
 
Body Mass Index, BMI – statistical measurement of weight according to 
height = weight (kg) / height
2 (m
2) 
 
Cancer Research UK, CRUK – National Cancer Charity based in United 
Kingdom. 
 
Clear Cell Renal Cell Carcinoma, CC-RCC – pathological variant of renal 
cell carcinoma distinguished by classical clear cytoplasm filled with lipid. 
 
Computed Tomography, CT – Radiological body imaging 
 
Cyan, Cy – colour 
 
Cyclooxygenase, COX – an enzyme that converts arachidonic acid to 
prostaglandin H2, the precursor for prostanoids 
 
Carbonic Anhydrase IX, CAIX - is an enzyme that catalyzes the rapid 
conversion of carbon dioxide and water into carbonic acid, protons and 
bicarbonate ions.  
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Deoxyribonucleic Acid, DNA – contains genetic instructions for 
development and function of all known living organisms 
 
Department of Health, DOH – organization (part of British Government) 
responsible for the running of health services within the UK 
 
Erythropoietin, EPO - is a glycoprotein hormone produced in the kidney 
that regulates red blood cell production, and consequently increases 
systemic oxygen delivery. 
 
Epidermal Growth Factor Receptor, EGFR – transmembrane receptor 
involved in cellular proliferation and angiogenesis. Primary ligand in 
Epidermal Growth Factor, EGF, although many other growth factors can 
bind to it. 
 
Ferrous Ion, Fe2+ - iron ion, an essential trace element in humans 
 
Glucose Transporter, GLUT1 - is a transmembrane protein involved in 
passive transport of glucose through cellular membranes 
 
Haematoxylin and Eosin, H&E, common histological cellular stain 
 
Insulin-like Growth Factor-2, IGF-2 - The insulin-like growth factors are 
polypeptides with high sequence similarity to insulin that form part of the 
IGF axis. 
 
Lactate Dehydrogenase, LDH – catalyses interconversion of pyruvate to 
lactate 
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Magnetic Resonance Imaging, MRI – medical imaging instrument which 
uses magnetic fields as its primary method to create computer images of the 
body. 
 
Matrix Metalloprotease, MMP – are zinc dependant endopeptidases capable 
of degrading extracellular matrix proteins and can process a number of 
bioactive molecules.  
 
Messenger RNA, mRNA – translates DNA into protein  
 
MicroRNA, miR – small non-coding RNA 
 
Monoclonal Antibody Ki-67, Ki-67 – proliferation marker 
 
Phosphatase and Tensin Homologue Gene, PTEN – tumour suppressor gene 
which plays a key role as the inhibitor to the Akt pro-tumourigenic pathway 
 
Placental Growth Factor, PIGF – a member of the Vascular Endothelial 
Growth Factor family expressed not only in placental cells but also in non-
placental cells such as endothelial cells. 
 
Polymerase Chain Reaction, PCR – amplification of small pieces of DNA 
for experimental quantification 
 
Protein53, p53 – tumour suppressor gene that blocks progression through 
the cell cycle in the event of DNA damage 
 
Reactive Oxygen Species, ROS – oxygen free radicals 
 
Renal Cell Carcinoma, RCC – cancer of the renal parenchyma 
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Ribonucleic Acid, RNA – translates DNA into protein 
 
Ribonucleic Acid interference, RNAi – molecular biological technique to 
block the translation of certain proteins. 
 
Secreted Protein, Acidic and Rich in Cysteine, SPARC / Osteonectin / 
BM40 - Non-collagenous, calcium-binding glycoprotein initially found in 
developing bone. An extracellular matrix protein. 
 
Thrombospondin, TSP – glycoprotein involved in cell adhesion, platelet 
aggregation, cell proliferation, tumour metastasis, and tissue repair. A major 
suppressor of angiogenesis. 
 
Tissue Factor, TF - membrane protein, which binds to coagulation factor 
VII/VIIa and initiates the coagulation cascade 
 
Transforming Growth Factor alpha, TGF alpha – growth factor that binds 
the Epidermal Growth Factor Receptor. 
 
Transforming Growth Factor beta, TGF beta – growth factor with several 
receptors including endoglin. 
 
Tumour Associated Macrophage, TAM – Macrophages that are present 
within tumor stroma, that have a different phenotype from normal tissue 
macrophages. 
 
Tumour Necrosis Factor, TNF - a multifunctional cytokine with effects on 
lipid metabolism, coagulation, insulin resistance and the function of 
endothelial cells lining blood vessels. 
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Tumour / Node / Metastasis, TNM – universal medical classification used to 
stage cancer advancement 
 
Ultrasound Scan, USS – sonographical medical imaging 
 
Vascular Endothelial Growth Factor, VEGF – a key angiogenic growth 
factor induced by hypoxia 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 1: 
Introduction  
CHAPTER 1  36 
 
Chapter 1:  Introduction 
 
1.1  Kidney Cancer 
1.1.1  Epidemiology 
Carcinoma of the kidney accounts for approximately 2% of all cancers in 
the UK, with on average 6700 new cases diagnosed each year (CRUK). The 
incidence is increasing by approximately 2% each year, due in part to the 
increased use of imaging modalities (Murai and Oya 2004). Despite this 
increase in early detection, about one third of patients who present with 
localised kidney cancer develop metastases and over half will die from the 
disease. Renal cancer, therefore, remains a significant cause of mortality and 
morbidity.  
 
1.1.2  Pathology 
Cancer of the renal parenchyma is termed Renal Cell Carcinoma, RCC and 
makes up approximately 85% of all tumours of the kidney. Further sub-
classification according to histopathological characteristics divides RCCs 
into Clear Cell (70-80%), Papillary (10-15%), Chromophobe (5%), 
Collecting Duct (Rare), and Unclassifiable (5%). The remainder of renal 
tumours consist of Transitional Cell Carcinomas (TCCs, 5-10%), Sarcomas, 
Wilms’ Tumour, as well as benign conditions such as renal cell adenoma, 
oncocytoma, and angiomyolipoma. 
 
The large majority of Kidney Cancers are Clear Cell RCCs, defined by their 
translucent cytoplasm under the light microscope, due to lipid accumulation 
by the tumour cells. Current techniques of DNA sequencing demonstrate 
that approximately 80% of these tumours have a mutation, large scale 
deletion or methylation in the Von-Hippel Lindau (VHL) tumour-
suppressing gene, rendering it non-functional (Kaelin 2002). The VHL gene 
is located on the short arm of chromosome 3 (3p26-25, molecular location  
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10,158,318 to 10,168,761) (See Figure 1.3). The significance of this will be 
discussed later in this chapter.  
 
 
 
Figure 1.1 - Fixed Surgical    Figure 1.2 - Clear Cell RCC with H & E  
Specimen of RCC  staining, demonstrating translucent 
cytoplasms 
 
Figure 1.3 - Position of VHL Tumour-suppressor gene on short-arm of 
Chromosome 3 
 
1.1.3  Primary Surgical Management 
Patients suspected to have a renal tumour will be further investigated using 
USS, CT or MRI imaging modalities. Approximately 75% of patients have 
no distant metastases at diagnosis, and can be offered curative treatment. 
Although novel treatments and being developed, such as Radio-Frequency 
Ablation and High-Intensity Focused Ultrasound, surgical resection remains  
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the gold-standard. Resection can be radical, partial or laparoscopic 
nephrectomy depending upon the size and position of the tumour as well as 
other variables such as premorbid conditions and patient body habitus. 
Following nephrectomy the surgical specimen is analysed by a specialised 
pathologist to determine pathological tissue diagnosis, tumour stage and 
Fuhrman grade. 
 
1.1.4  Tumour T Stage  
Pathological stage using the TNM classification has been modified over the 
past few decades. The principle of staging by defining a tumour by its size 
and level of invasion remains the same, but the boundaries of invasion have 
evolved as we have discovered the significance of each. Before 2002 the 
four stage system described T1 as less than 7cm; T2 as greater than 7cm but 
contained within the renal capsule; T3a as invasion into the renal capsule or 
adrenal gland; T3b invasion into renal vein or IVC below the diaphragm; 
T3c as invasion into the IVC above the diaphragm; and T4 as invasion 
beyond Gerota’s fascia. In 2002, the American Association of Pathologists 
made three changes to the classification. These were: i) sub-division of T1 
into T1a <4cm, and T1b 4-7cm; ii) invasion of the renal sinus to be 
classified with extracapsular invasion (T3a); and iii) invasion of the 
muscular segmental branches of the renal vein within the renal sinus, to be 
equivalent to renal vein invasion (T3b) (Cancer 2002). These changes, 
especially the inclusion of renal sinus invasion, was often not specifically 
assessed in pathological examination prior to 2002 and has meant that as 
many as 80% of T2 tumours before the new system, would now be 
classified as T3 (Bonsib 2005). 
 
1.1.5  Fuhrman Grade 
Nuclear grade in RCCs was evaluated in 1982 by S. A. Fuhrman, based on 
103 RCC H & E sections assessed under the light microscope. Fuhrman 
grade has subsequently been adopted as the standard classification of  
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nuclear grade for RCCs and is defined as a score of 1 to 4 based on 
increasing nuclear size, irregularity and nucleolar prominence (Fuhrman, 
Lasky et al. 1982).  
 
1.1.6  Management of Advanced RCC 
Approximately one third of patients with RCC will have metastasis at 
diagnosis, whilst another third will develop metastasis following primary 
nephrectomy. These patients have a poor prognosis with 2-year survival 
only 10-20% (Campbell, Flanigan et al. 2003). Historically, biologic therapy 
with interferon (IFN-alpha) and interleukin-2 (IL-2) has been the mainstay 
of treatment for patients with metastatic RCC, largely due to the 
radioresistance and chemoresistance of RCC (Yagoda, Petrylak et al. 1993; 
Deschavanne and Fertil 1996; Motzer and Russo 2000). Treatment with 
IFN-alpha and/or high dose IL-2, however only achieves response rates in 
10-20% of patients (Fyfe, Fisher et al. 1995; Yang, Sherry et al. 2003; 
McDermott, Regan et al. 2005).  
 
There is some evidence of spontaneous regression of distant metastatic renal 
deposits following resection of the primary tumour, however this 
phenomenon remains rare. However, several other potential arguments for 
the role of cytoreductive surgery in advanced RCC exist. These include 
reducing the tumour burden and hence removing a source for growth factors 
and cytokines and avoiding the possibility of an immune sink. Several 
studies have evaluated various combinations of immunotherapy with and 
without adjuvant nephrectomy. The European Organisation for Research 
and Treatment of Cancer (EORTC) 30947 and Southwest Oncology Group 
(SWOG) 8949 trials were prospectively randomised clinical trials 
comparing radical nephrectomy plus INF-a compared with IFN-a alone 
(Mickisch, Garin et al. 2001; Flanigan, Salmon et al. 2001). Combined 
analysis of the two trials showed a median survival of 13.6 months for 
nephrectomy plus IFN-a compared with 7.8 months for IFN-a alone. There  
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has not yet been a randomised trial to compare the efficacy of IFN-a to IL-2 
after cytoreductive nephrectomy. However, Pantuck et al. have performed a 
retrospective study using the eligibility criteria from the SWOG 8949 trial to 
identify a comparable population treated with IL-2 following nephrectomy 
from the UCLA Kidney Cancer Database. They identified 89 patients and 
compared the survival of these patients with the survival of the 120 patients 
that received surgery plus IFN-a in the SWOG trial. They found that the 
median survival in patients treated with nephrectomy plus IL-2 was 
approximately 30% (4 months) longer than the nephrectomy plus IFN-a arm 
in the SWOG trial. There are currently no data on nephrectomy following 
any of the novel tyrosine kinase inhibitors, and this must be further 
evaluated using randomised trials in metastatic RCC. 
 
Recent discoveries in the genetic basis and activating mechanisms of RCC 
have led to the development of targeted approaches to therapy. 
Bevacizumab, a VEGF neutralising antibody, was the first of these novel 
therapies to demonstrate a benefit in advanced RCC, prolonging time to 
progression (Yang, Haworth et al. 2003). More recently Sunitinib and 
Sorafenib, multi-target tyrosine kinase inhibitors, have both been shown to 
significantly improve progression-free survival (Escudier, Eisen et al. 2007; 
Motzer, Hutson et al. 2007), whilst other trials are ongoing to evaluate 
inhibitors to the mTOR pathway (located upstream from the HIF pathway), 
as well as other potential targets (including HIF) as our understanding of the 
biology improves. 
 
1.1.7  Mortality 
Kidney cancer is the 10
th commonest cause of death in men and the 13
th 
commonest in women, with a rate of 3600 deaths per year in the UK. The 1, 
5 and 10-year survival rates in the UK are 60%, 42% and 38% respectively 
(data from 2000/2001) (CRUK; Office for National Statistics, 2007). See 
Table 1.1.  
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  Year of Nephrectomy 
     
  1981 - 1990  2000 - 2001 
     
1 year survival  50%  60% 
     
5 year survival  35%  42% 
     
10 year survival  28%  38% 
     
Table 1.1 – 1, 5 and 10-year survival (kidney cancer specific death) 
following nephrectomy (Office for National Statistics, 2007). 
 
1.1.8  Trends over time 
From 1975 to 2003 incidence rates in men and women have increased by 
69% and 100% respectively, in the UK. This may be partly due to the 
increasing average age of the population, with the majority of the increases 
seen are in men over 65, and in women over 55 years old (Coleman, Rachet 
et al. 2004; Office of Public Sector information). Another contributing 
factor is the increasing use of diagnostic imaging, with a subsequent rise in 
the incidental finding rate of a renal mass. There has been a 73% rise in the 
use of USS and CTs in the USA from 1986 to 1994 (Chow, Devesa et al. 
1999). However, this has also demonstrated a significant rise in 
asymptomatic metastatic tumours, so the improved survival of kidney 
cancer may not be wholly accountable to this (Chow, Devesa et al. 1999). 
Furthermore there have been stable rates of pelvic cancer diagnoses over 
this time, where a similar rise would otherwise be expected (Chow, Devesa 
et al. 1999; Tate, Iddenden et al. 2003). 
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1.1.9  Risk Factors 
Established risk factors for kidney cancer are increasing age, sex (male > 
female), obesity (approximately 25% of RCC could be attributable to 
obesity, with a relative two-fold increase in risk for patients with a BMI in 
the highest category); smoking (two-fold increase in risk for RCC); diet 
(possibly meat and dairy products increase risk, whilst antioxidants within 
fruit and vegetables decrease risk); other medical conditions (such as 
acquired cystic kidney disease, end-stage renal failure, hypertension). 
Reviewed in (CRUK). 
 
1.1.10  Prognostic Algorithms 
 
Several groups have sought to build prognostic algorithms by combining 
multiple prognostic factors. These may provide superior predictive 
information for individual patients and identify those at low risk for whom 
follow-up, including imaging can be safely reduced and select those at high 
risk for adjuvant therapies. 
 
The UCLA Integrated Staging System (UISS) uses stage (1997 TNM), 
Fuhrman Grade, and the Eastern Cooperative Oncology Group (ECOG) 
performance status to stratify patients into low, intermediate or high risk 
categories (Zisman, Pantuck et al. 2002).  
 
The Memorial Sloan Kettering Cancer Centre (MSKCC) nomogram 
includes clinical presentation (incidental or symptomatic) (Sorbellini, 
Kattan et al. 2005). This was of prognostic significance in cohort surgical 
studies (Ficarra, Prayer-Galetti et al. 2003; Lee, Katz et al. 2002; Patard, 
Ridriguez et al. 2002) but not in a population based study Gudbjartsson, 
Thoroddsen et al. 2005). Other factors in the nomogram are tumour size, 
stage (2002), Fuhrman grade, the presence of necrosis, and/or vascular  
CHAPTER 1  43 
 
invasion. The nomogram of a 5-year predicted probability of freedom from 
recurrence is available at nomograms@mskcc.org. 
 
The Mayo Clinic algorithm (Leibovich, Blute et al. 2003) is based on 
pathological tumour stage (2002), nodal status, tumour size (10cm cut-off), 
nuclear grade, and histological tumour necrosis. This large study including 
1671 patients shows good discrimination for the 5-year risk of recurrence 
between low, intermediate and high risk groups, and has been independently 
validated (Ficarra, Martignoni et al. 2006).  
 
The prognostic significance of molecular markers is discussed later in this 
chapter. Prognostic algorithms including these markers are yet to improve 
on the MSKCC or Mayo nomograms, however their continued investigation 
is of great interest as this may elucidate which patients are likely to respond 
to the developing novel therapies in development. 
 
1.2  Data Collection 
There is an increasing need to collect data on cancer patients from surgical 
departments, oncological departments and for research purposes. Clinical 
audit is an essential requirement of clinical governance for health care 
professionals and good data collection is a vital component of this process. 
Furthermore, National Health Service (NHS) trusts are putting increasing 
emphasis on clinical audit since it has become a requirement for foundation 
trust status.  
 
Professional bodies such as the British Association of Urological Surgeons 
(BAUS) are also increasingly keen to audit all complex cancer surgery for 
the assessment of these procedures, and to evaluate developing techniques 
in urology cancer surgery. The expanding knowledge of molecular biology 
and the subsequent growing number of novel targeted therapeutic agents in  
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Oncological treatment will require careful patient / tumour selection. The 
assessment of which tumour molecular profile suits which targeted therapy 
will largely depend upon large scale profiling on tumours and their response 
to these new treatments.  
 
1.3  Tissue Collection 
The collection of cancer specimens for molecular biological assessment is 
clearly important to further our knowledge of cancer biology and allow 
translation into targeted therapies. The introduction of the Human Tissue 
Act in 2004 has meant that human tissue collection for research purposes is 
now carefully regulated by the Human Tissue Authority under the 
guidelines of the Act. It is therefore important that we have robust systems 
in place to fulfil these requirements.  
 
1.4  Tumour Biology 
1.4.1  Hypoxia 
Oxygen homeostasis and protection from episodes of low oxygen tension in 
human tissues is important for cell survival. There are a number of 
physiological and pathological scenarios that place the cell in hypoxic 
conditions warranting adaptation to the stressful environment. 
 
In hypoxia, oxidative phosphorylation is deceased with subsequent 
reduction of ATP production. A responsive increase in glycolysis 
compensates for this ATP reduction to some degree, but many ATP-
dependent processes such as protein translation are decreased in hypoxic 
cells. Despite this, the cell must adapt to the hypoxic environment via 
increased oxygen delivery systemically and locally, as well as protect itself 
from secondary effects of hypoxia, such as decreased pH. Therefore, in a 
background of decreased total protein translation, specific upregulation of  
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protective mechanisms safeguard the cell from hypoxic stress. This process 
is primarily regulated by a transcription factor known as Hypoxia Inducible 
Factor, HIF. 
 
In renal tumours, neovascularisation often lags behind tumour growth, 
leaving areas of hypoxia. This decrease in oxygen tension activates HIF, 
causing transcription of many protumourigenic factors that protect the 
tumour cells from the stressful environment. Induced genes include those 
involved in angiogenesis (VEGF, VEGFR-1, TP, Ang2), glucose 
metabolism (glucose transporters GLUT1, aerobic glycolysis LDH5), 
apoptosis / autophagy (BNIP3), cellular de-differentiation (Oct-4), 
proliferation (insulin-like growth factors IGF-2, cell cycle progression 
cyclin D1 ) and pH regulation (carbonic anhydrase IX) (Harris 2002).  
 
The loss of pVHL has been demonstrated as a characteristic finding in clear 
cell carcinoma of the kidney, and in the key genetic variant in the 
pathogenesis of the VHL syndrome. As discussed shortly, a lack of a 
functional VHL protein product leads to constitutive activation of the HIF 
pathway. 
 
1.4.2  Hypoxia Inducible Factor, HIF 
1.4.2.1   Background 
Hypoxia-Inducible Factor 1, HIF-1 was initially identified as a 
transcriptional activator of erythropoietin (a glycoprotein regulating red cell 
production in the kidney), under hypoxic conditions (Semenza and Wang 
1992) (Wang and Semenza 1995). Numerous other factors have 
subsequently been identified to be induced by HIF and many of these genes 
are also known to be similarly regulated in cancer, suggesting an important 
regulatory role of HIF in tumours. HIF is highly conserved in eukaryotes 
from C elegans through to humans, highlighting its fundamental role in 
normal physiological cell functions.  
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1.4.2.2   Structure 
HIF1 is composed of a 120-kDa HIF1-alpha subunit complexed with a 91- 
to 94-kDa HIF1-beta subunit. They are both basic-helix-loop helix proteins 
containing a PAS domain. HIF1-alpha located on chromosome 14q21-q24 
(Semenza, Agani et al. 1997) is closely related to Sim, and HIF1-beta is aryl 
hydrocarbon receptor nuclear translocator ARNT, which heterodimerise 
with either HIF1-alpha or AHR. HIF1-alpha protein levels increase under 
hypoxic conditions and subsequently return to normal state under normoxia 
(Wang, Jiang et al. 1995). HIF alpha contains an N-terminus bHLH domain 
that mediates binding to consensus DNA sequences (CTACGTGCT ) in the 
promoter region of target genes (Murre, McCaw et al. 1989) (Semenza and 
Wang 1992) (Semenza, Koury et al. 1991; Wang, Jiang et al. 1995).  
 
 
Figure 1.4 – Structure of HIF alpha 
 
1.4.2.3   HIF Degradation Pathway 
In normal physiological conditions HIF-alpha undergoes rapid degradation. 
The proline residues (Pro402 - Pro564 in HIF-1 and Pro 406 – Pro 531 in 
HIF-2) (Bruick and McKnight 2001) (Epstein, Gleadle et al. 2001) within its 
oxygen-dependent degradation domain (ODD) are hydroxylated by one of a 
3 member family of prolyl hydroxylase domain, containing proteins 1-3 
(PHDs 1-3). These enzymes are oxygen, Fe2+, ascorbate and 2 oxoglutarate 
dependent and their action is enhanced by the presence of OS-9, (a 
ubiquitously expressed protein of no other known function). This 
hydroxylation allows interaction with von Hippel Lindau protein (pVHL),  
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(the recognition component of an E3 ubiquitin ligase) which subsequently 
promotes a larger complex formation with elongin-B, elongin-C and cullin-
2. This is then rapidly destroyed by 26S proteasomes.  
 
 
Figure 1.5 – HIF alpha degradation pathway 
 
1.4.2.4   HIF Activation in Hypoxia 
In times of insufficient oxygen the prolyl hydroxylation of HIF-alpha is 
reduced, allowing the HIF alpha and beta subunits to combine at nuclear 
HREs (hypoxic response elements) at a number of target genes (Ivan, 
Kondo et al. 2001) (Jaakkola, Mole et al. 2001). Subsequent interaction with 
coactivators CBP and p300 activates transcription and thus gene expression 
(Ruas, Poellinger et al. 2005).  
 
Figure 1.6 – HIF activation  
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In many target genes HIF binding to HREs is sufficient for gene induction, 
although in others synergistic co-operation with other transcription factors 
such as Smad3, HNF4, ATF1/CREB1, AP1 and Ets-1 is required (Bracken, 
Whitelaw et al. 2003). (See recent reviews (Pugh and Ratcliffe 2003) 
(Harris 2002; Hirota and Semenza 2006)). 
 
1.4.2.5   Alternative Pathways of HIF Activation 
An alternative mechanism for HIF-alpha activation in hypoxia is regulated 
by Factor Inhibiting HIF (FIH). HIF has two transactivation domains, NAD 
(N-terminal activation domain) and CAD (C-terminal activation domain). 
The CAD overlaps with the ODD binding pVHL complex and the NAD 
offers the alternative regulatory mechanism. Oxygen dependent 
hydroxylation of the asparagine residue (Asn 803 – HIF1, Asn 851 – HIF2) 
on the CAD blocks interaction with the transcriptional coactivators CBP 
(CREB binding protein) and p300 previously mentioned. This hydroxylation 
is enabled through the enzyme FIH that requires oxygen as a co-factor. 
Therefore in hypoxic conditions, hydroxylation of this asparagine residue is 
avoided allowing HIF transcriptional activation (recently reviewed in (Liu 
and Simon 2004)). 
 
 
Figure 1.7 – Alternative pathway of HIF alpha activation 
 
HIF-1 can also be activated by interaction with reactive oxygen species 
(ROS) possible via inhibition of PHD hydroxylation (Liu and Simon 2004), 
the source of which may be from mitochondria as oxygen tension drops.  
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Increased ROS production is also seen in response to radiation treatment, 
where there is subsequent increased HIF-1 expression and VEGF production 
(Moeller, Cao et al. 2004). The source of which is likely to be inflammatory 
cells such as macrophages. 
 
Low oxygen tension is the primary activator of the HIF pathway, although 
growth factors (e.g. insulin, EGF, PDGF) and cytokines (e.g. TNF alpha, 
interleukin-1 beta) have also been shown to initiate the HIF pathway 
although the amplitude of induction is lower (Zelzer, Levy et al. 1998; 
Haddad and Land 2001; Stiehl, Jelkmann et al. 2002; Treins, Giorgetti-
Peraldi et al. 2002; Zhou, Schmid et al. 2003). HIF hydroxylation and 
subsequent degradation is also dependent upon sufficient levels of iron, 
ascorbate and 2-oxoglutarate. Therefore a deficiency of any of these co-
factors can activate the HIF system in-spite of sufficient oxygen levels. HIF 
activity is also enhanced by oncogenes such as Human Epidermal Growth 
Factor Receptor 2 (HER2), H-ras and v-Src (Jiang, Agani et al. 1997; Chen, 
Pore et al. 2001; Laughner, Taghavi et al. 2001). Interestingly, every 
oncogene pathway investigated has been reported to enhance HIF function 
(Blancher, Moore et al. 2000; Vogelstein and Kinzler 2004). This is likely 
related to a fundamental link between proliferation, the generation of 
hypoxia, metabolite consumption and the need to increase blood flow and 
oxygen delivery locally and systemically (Maxwell, Pugh et al. 2001).  
 
1.4.2.6   Regulation of HIF Synthesis 
Regulation of HIF-1 mRNA translation to protein is still necessary, although 
not mediating rapid responses to hypoxia, it is clearly essential to maintain 
protein synthesis. It can be an important contribution to the mechanisms by 
which oncogenes activate HIF. Thus HER2 can activate two intracellular 
signalling pathways PI3K and MAPK, which in turn lead to activation of the 
eukaryotic translation initiation factor 4E (eIF-4E) which increases the rate 
at which HIF-1 mRNA is translated into protein (Semenza 2003). These  
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pathways are subject to positive feedback loops as HIF-1 can induce 
expression of many growth factors, and their receptors. 
 
1.4.2.7   HIF isoforms 
HIF family comprises HIF-1 alpha (aka Member of PAS1 (MOP1)); HIF-2 
alpha (aka endothelial PAS domain protein 1 (EPAS1)); HIF-3 alpha (aka 
MOP3); HIF-1 alpha like protein (MOP2 / HLF); and HIF related factor 
(HRF). HIF-1 alpha and HIF-2 alpha both dimerise with HIF-beta and 
subsequently bind to nuclear Hypoxia Response Elements, HREs to regulate 
certain genes in a hypoxia-inducible manner (Wiesener, Turley et al. 1998; 
Ema, Hirota et al. 1999). HIF-1 and HIF-2 contain 48% sequence homology 
but have significant differences in their C-terminal sequences. This may 
explain the findings in specific knockdown studies of HIF-1 and HIF-2 in 
embryonic stem cells, mouse embryos and human cancer cells that there is 
differential function and target gene expression between the two isoforms 
(Ema, Taya et al. 1997; Hu, Wang et al. 2003; Pugh and Ratcliffe 2003) 
(Raval, Lau et al. 2005) (Park, Dadak et al. 2003; Sowter, Raval et al. 2003). 
This is particularly apparent in the difference between HIF-2 predominance 
in renal cancer which promotes tumour growth (Kondo, Klco et al. 2002; 
Maranchie, Vasselli et al. 2002) and breast cancer where growth is inhibited 
(Blancher, Moore et al. 2000). There is increased selectivity of HIF target 
genes to HIF-1 or HIF-2 in VHL defective cells (such as the majority of 
CC-RCC) compared to other cells. In CC-RCC cell lines and a mouse model 
HIF-2 encourages tumour growth whilst HIF-1 overexpression suppressed 
this growth, and that the two isoforms have a reciprocal relationship (Raval, 
Lau et al. 2005). 
 
The distribution of HIF-1 and HIF-2 differs in normal tissue of rodents. 
HIF-1 widely expressed – predominantly in epithelial cells, while HIF-2 has 
a more localised expression pattern, predominantly in interstitial fibroblasts 
and endothelial cells (Rosenberger, Mandriota et al. 2002). HIF2 has higher  
CHAPTER 1  51 
 
expression in highly vascular organs such as the heart, placenta and lungs, 
bone marrow macrophages, kidney epithelial cells, liver parenchyma, 
cardiac myocytes and pancreatic parenchymal cells in the adult, and lung 
and neural crest derivatives in the embryo. (Tian, McKnight et al. 1997; 
Talks, Turley et al. 2000; Wiesener, Jurgensen et al. 2003) (Ema, Taya et al. 
1997). In humans however, there are many cells that express both isoforms 
of HIF alpha or neither. 
 
An alternative splice variant of the HIF-3 locus, termed inhibitory PAS, 
negatively regulates HIF induced gene expression, in particularly VEGF. 
This HIF-3 alpha isoform may have a role in maintaining an avascular 
environment in certain tissues such as the cornea, and possibly forms a 
negative feedback loop to regulate HIF hypoxic response (Makino, Kanopka 
et al. 2002).  
 
 1.4.2.8  HIF and Embryonic Vascular Development 
HIF-1 is expressed in all tissues during development and is essential for 
embryonic vasculogenesis, angiogenesis and haematopoiesis in part by 
promoting the production of VEGF. 
 
Mesenchyme derived endothelial progenitor cells are produced in the yolk 
sac and embryo in a HIF dependent manner (Ramirez-Bergeron, Runge et 
al. 2004). They differentiate during development under the regulation of 
VEGF and bFGF mediated signalling (Kennedy, Firpo et al. 1997; Faloon, 
Arentson et al. 2000; Conway, Collen et al. 2001) to form the primary 
capillary plexus of the embryo. 
   
Via studies in HIF1-alpha negative embryonic stem cells, Iyer et al. in 1998 
demonstrated that the absence of HIF1-alpha resulted in reduced glucose 
transporter, glycolytic enzymes and VEGF RNA as well as decreased 
proliferation. HIF1-alpha negative embryos resulted in developmental arrest  
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and lethality at day 10, with notable neural tube defects, cardiovascular 
malformations and marked cell death within the cephalic mesenchyme. 
Comparable HIF1-alpha positive embryos showed increased HIF1-alpha 
expression at the same time-point (Iyer, Kotch et al. 1998; Ryan, Lo et al. 
1998; Kotch, Iyer et al. 1999). 
 
HIF-2 is expressed in the lung and neural crest derivatives in the embryo 
and is essential for embryonic vascular development (Ema, Taya et al. 1997; 
Tian, Hammer et al. 1998). In studies with HIF-2 negative mouse embryos 
lethality occurred between 9 and 14 days due to disorganisation of blood 
vessel growth within the embryo and yolk sac or later due to 
cardiorespiratory failure secondary to decreased lung surfactant or 
catecholamine production. However, this was rescued by reintroduction of 
HIF-2 (Tian, Hammer et al. 1998; Peng, Zhang et al. 2000; Compernolle, 
Brusselmans et al. 2002; Duan, Zhang-Benoit et al. 2005). 
In HIF-1 / HIF-2 knockdown studies in mice, most genes were responsive 
only to HIF-1 knockdown, showing little or no effect to HIF-2 siRNA apart 
from EPO which appears to be HIF-2 specific. However the target gene 
specificity to either HIF-1 or HIF-2 can be overcome in certain cell types 
(Warnecke, Zaborowska et al. 2004; Chavez, Baranova et al. 2006). 
 
In mouse embryo fibroblasts (MEFs) HIF-2 was detected within the 
cytoplasm regardless of oxygen tension, but was transcriptionally inactive 
until it was extrinsically overexpressed whereupon it translocated to the 
nucleus and initiated hypoxic gene expression (Park, Dadak et al. 2003). 
FIH selectively inhibits HIF-1 in low oxygen tensions, but not HIF-2 in 
MEFs, suggesting that the balance between HIF-1 and HIF-2 may allow 
cell-specific modulation of the hypoxic response (Park, Dadak et al. 2003). 
 
Mice lacking HIF-2 that survive development demonstrate a phenotype of 
multiple organ pathologies, transformed gene expressions and biochemical  
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defects (including retinopathy, hepatic steatosis, cardiac hypertrophy, 
skeletal myopathy, hypocellular bone marrow, azoospemia, mitochondrial 
abnormalities, decreased transcriptional activation of the primary 
antioxidant enzymes and increased ROS). This suggests HIF-2 may play a 
role in the maintenance of mitochondrial and ROS homeostasis 
(Scortegagna, Ding et al. 2003).  
  
HIF beta is ubiquitously expressed in the embryo. HIF beta negative 
embryos die at day 10 in a manner similar to HIF-1 negative embryos 
(Maltepe and Simon 1998; Cowden Dahl, Fryer et al. 2005). This is 
primarily due to yolk sac haemopoietic and angiogenic development 
problems. (Adelman, Gertsenstein et al. 2000; Ramirez-Bergeron and Simon 
2001; Ramirez-Bergeron, Runge et al. 2006). These effects may be 
secondary to decreased VEGF production, which regulates endothelial cell 
production and vascular morphogenesis. (Ramirez-Bergeron, Runge et al. 
2006) 
 
1.4.2.9   HIF and Tumour Associated Macrophages 
Large numbers of circulating monocytes are attracted to hypoxic tumours 
along chemotaxic gradients (Kelly, Davison et al. 1988) (Leek, Harris et al. 
1994). They migrate across the vascular endothelium becoming Tumour-
Associated Macrophages, TAMs - a process regulated to a large degree by 
intra-tumoural hypoxia. Their presence within tumours can be anti- or pro-
tumourigenic due to their secondary effects on antigen presenting abilities to 
cytotoxic T-cells, or their ability to secrete tumour mitogens and angiogenic 
promoters (including HIF) (Leek and Harris 2002). This balance appears to 
depend on the tumour microenvironment, with high TAM infiltration in 
some tumour types being beneficial to survival (stomach, colon, and 
melanoma), whilst in others their presence is detrimental (breast, prostate, 
bladder, endometrial, kidney and lymphoma). (Lewis and Pollard 2006) 
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HIF activation within the tumour induces secretion of a number of factors 
that aid monocyte adhesion and extravasation, as well as TAM migration to 
the hypoxic centre of the tumour (Balkwill 2004) (Murdoch, Giannoudis et 
al. 2004). The most widely studied hypoxia-induced chemoattractant is 
VEGF, which not only triggers the VEGF-R1 receptor on TAM cell surface 
(Barleon, Sozzani et al. 1996), but may also initiate a positive feedback 
mechanism that amplifies the signal (Lewis, Landers et al. 2000).  
 
Other important hypoxia induced chemoattractants include stromal cell-
derived factor-1 (SDF-1) (Schioppa, Uranchimeg et al. 2003), Endothelin-1 
(Grant, Loizidou et al. 2003), Endothelin-2 (Grimshaw, Wilson et al. 2002), 
transforming growth factor-alpha (TGF-alpha) (Gunaratnam, Morley et al. 
2003) and EMAP II (endothelial-monocyte activating peptide II) 
(Matschurat, Knies et al. 2003). Macrophage migration inhibitory factor 
(MIF), a pleiotrophic cytokine, is also released in response to hypoxia and 
serves to retain the TAMs within the hypoxic environment by reducing 
further migration (Bacher, Schrader et al. 2003).  
 
The phenotype of these macrophages changes upon migration into the 
tumour where they then function to promote angiogenesis (Leek, Lewis et 
al. 1996) (Lewis, Landers et al. 2000) (Miles, Happerfield et al. 1994), 
remodel the surrounding matrix (Petrella, Lohi et al. 2005) (Burke, 
Giannoudis et al. 2003) and suppress the adaptive immunity (Sica, Schioppa 
et al. 2006). This leads to a predominant pro-angiogenic phenotype in 
tumours with high a TAM component (Leek, Lewis et al. 1997).  
 
1.4.2.10  HIF Regulated Gene Expression 
 
As mentioned earlier in this chapter, EPO was the first target gene 
associated with HIF, and there are now many more (see table 1.2). 
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   Secreted Factors  Adrenomedullin 
     Angiopoietins  
     Angiopoietin 2  
     Angiopoietin like 4  
  
 
Connective Tissue Growth Factor, CTGF 
   Endothelin 1 
     Endothelin 2 
     Erythropoietin EPO 
     Hepatocyte Growth Factor, HGF 
     Interleukin-8, IL-8 
     Inducible Nitric Oxide Synthase, iNOS  
     ORP150 VEGF chaperone  
     Osteopontin 
     Platelet Derived Growth Factor beta, PDGF beta  
     Stromal Cell-Derived Factor-1, SDF1 (CXCL12) 
     Spingosine 1 Phosphate, S1P 
     Stanniocalcin 1 
     Stanniocalcin 2 
     Transforming Growth Factor beta 2, TGF beta 2 
     Transforming Growth Factor beta 3, TGF beta 3 
     Tie2 
     Vascular Endothelial Growth Factor, VEGF  
       
   Tethered Ligand  Delta-like 4, DLL4 - Notch signalling  
       
   Cell Adhesion  Integrins  
     Tenascin (Hexabrachion) 
       
   Transmembrane Receptors  VEGF Receptor 1, VEGFR 1  
     VEGF Receptor 2, VEGFR 2  
     CXCR4, Fusin 
     Transferrin receptors 
     Adenosine receptors 
       
   Copper Pathways  Caeruloplasmin  
       
   Extracellular Matrix Proteases  Lysyl Oxidase, LOX 
     Matrix Metalloproteinase 1,MMP 1 
     Matrix Metalloproteinase 2,MMP 2 
     Matrix Metalloproteinase 9,MMP 9 
     Plasminogen activator inhibitor-1, PAI1  
     Urokinase receptor  
Table 1.2 – HIF-1 alpha target genes 
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The methods that have been used for looking at HIF-dependent gene 
expression include screening for:  
1. Genes with increased expression secondary to HIF activated cells (e.g.    
VHL mutated cells, hypoxic cells).  
2. Genes with decreased expression secondary to targeted HIF inactivation.  
3. Genes that contain a HIF binding site 5’-RCGTG-3’ at cis acting HREs. 
 
There may be as many as 1-5% of all genes that can be expressed in 
response to hypoxia in a cell / tissue specific manner (Semenza 2003). This 
may be reflective of the fact that although the main role of HIF is the direct 
regulation of primary transcripts, there is also interaction with other 
signalling pathways that can amplify the hypoxic signal. Examples of this 
include HIF enhancing notch signalling which subsequently inhibits 
differentiation of certain cell types (Gustafsson, Zheng et al. 2005); HIF 
decreasing c-myc’s effect on p21 resulting in cell cycle arrest (Koshiji, 
Kageyama et al. 2004); as well as other effects on p53, c-Jun and NF-
kappaB (reviewed in (Hickey and Simon 2006)) 
 
1.4.2.11  HIF in Adult Tissue 
Within physiologically normal adults, HIF-1 is important in erythropoiesis 
and pulmonary remodelling in response to chronic hypoxia (Yu, Shimoda et 
al. 1999), wound healing (Elson, Ryan et al. 2000), brain spatial memory 
function (Tomita, Ueno et al. 2003), breast tissue differentiation and 
lactation (Seagroves, Hadsell et al. 2003) and cardiac contractility (Huang, 
Hickey et al. 2004). 
 
Pathophysiological angiogenesis, primarily through ischaemic injury causes 
induction of the HIF pathway and increased HIF-1 expression, as well as its 
associated target genes in many human tissues including the brain, heart, 
lung and eye (Yu, Frid et al. 1998; Bergeron, Yu et al. 1999; Ozaki, Yu et 
al. 1999; Lee, Wolf et al. 2000).  
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1.4.3  HIF in Cancer 
1.4.3.1   HIF and VHL syndrome 
VHL Syndrome is an autosomal dominant condition from an inherited 
mutation in one allele of the VHL gene located on the third chromosome. 
Subsequent mutation or loss of the remaining allele in somatic tissues leads 
to tumour development at that site. Features of this syndrome include 
angiomatosis (collections of disorganised capillaries in various organs), 
haemangioblastomas (tumours of the CNS, especially the cerebellum), 
phaeochromocytomas (tumours of the adrenal medulla), and clear cell 
tumours of the kidney. The VHL gene is also inactivated in a large 
percentage of haemangioblastomas and RCCs via mutation, large scale 
deletions or methylation (Kaelin 2002). An unanswered problem is why 
malignant tumours form in the kidney, but with the same mutations only 
haemangiomas form in the CNS. 
 
The loss of the functional protein product of VHL leads to constitutive 
activation of HIF, with the resultant increase in expression of its target 
genes controlling angiogenesis, proliferation, glucose metabolism, and pH 
regulation. 
 
That a hereditary cancer syndrome results directly in HIF upregulation has 
provided strong evidence for the role of HIF in cancer, but it is a puzzle as 
to why there are no mutations in HIF leading directly to its stabilisation. 
VHL has additional functions and partners that may be required, a subject of 
much investigation. Nevertheless, there is a striking correlation of genes 
induced by hypoxia and HIF and those regulated by VHL (Wykoff, Pugh et 
al. 2000).  
 
1.4.3.2   HIF Protein Expression in Cancer 
Identification of HIF alpha within normal and cancerous tissues with 
immunohistochemistry has shown that there is much variation between  
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different tissue types. Immunostaining is predominantly nuclear and 
generally strongest in perinecrotic regions (where presumably hypoxia is 
maximal) and there is often co-localisation of HIF expression and VEGF 
(Talks, Turley et al. 2000).  
 
The majority of benign tissues do not express stabilised HIF-alpha; however 
it is commonly over-expressed in malignant tissues. The pattern of 
expression within tumours appears partly dependent upon the mechanism of 
activation. Diffuse expression is seen in tumours with mutations within the 
HIF degradation pathway such as clear cell RCC with its common mutation 
in the VHL gene. High and more localised expression is seen in peri-
necrotic areas where the HIF activation is via hypoxia. (Krieg, Haas et al. 
2000; Wykoff, Beasley et al. 2000; Zagzag, Zhong et al. 2000).  
 
Hypoxia is the primary activator of HIF in tumours but other mechanisms 
such as mutations in tumour suppressor genes such as VHL, p53, PTEN can 
result in increased HIF (Maxwell, Wiesener et al. 1999; Ravi, Mookerjee et 
al. 2000; Zundel, Schindler et al. 2000). Also activation of oncogenes such 
as v-SRC, EGFR, and HER2 and subsequent signalling via the 
phosphatidyllinositol-3-kinase (PI-3K) pathway and mitogen-activated 
protein kinase (MAPK) pathway increase or amplify HIF activation (Jiang, 
Agani et al. 1997; Chen, Pore et al. 2001; Laughner, Taghavi et al. 2001). 
 
Interaction with the microenvironment and stroma is also important. HIF-1 
deficient mouse astrocytoma cells when placed in a vessel-poor 
subcutaneous environment resulted in necrosis, poor growth and poor vessel 
development. However, when these same cells were placed in a vessel-rich 
environment (brain parenchyma) they grew quickly with extensive invasion. 
(Blouw, Song et al. 2003).  
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HIF-1 alpha protein is significantly increased in all human cancers studied 
(glioblastoma multiforme, prostate, breast, lung, pancreatic), and correlates 
with highly vascular tumours (Semenza 2002; Brahimi-Horn and 
Pouyssegur 2005). HIF-2 alpha can also be identified in these tumours, 
however its expression level is generally lower, apart from hepatocellular 
carcinoma where it is more pronounced (Bangoura, Yang et al. 2004) and in 
RCC where HIF-2 seems to predominate in more advanced tumours 
(Mandriota, Turner et al. 2002). 
 
1.4.3.3   Xenograft studies 
In-vivo studies determining the effect of HIF-1 in experimental xenograft 
tumours, demonstrate a HIF-1 dependent stimulatory effect on tumour 
growth and angiogenesis. The HIF dependent effect on angiogenesis is more 
distinct in studies on human cancer cells and is primarily due to VEGF 
production, although there is variation dependent upon the specific 
microenvironment and cell type. (Ryan, Lo et al. 1998) (Maxwell, Dachs et 
al. 1997) (Hopfl, Wenger et al. 2002) (Carmeliet, Dor et al. 1998) (Kung, 
Wang et al. 2000; Blouw, Song et al. 2003)   
 
1.4.3.4   Prognosis 
The net effect of HIF activation on outcome appears to vary depending upon 
the origin of the primary tumour. Positive correlation with pathological 
features and poor prognosis have been reported in brain (Korkolopoulou, 
Patsouris et al. 2004), breast (Schindl, Schoppmann et al. 2002), bladder 
(Theodoropoulos, Lazaris et al. 2004), ovarian (Birner, Schindl et al. 2001) 
and cervical tumours (Birner, Schindl et al. 2000), whilst HIF-1 over 
expression has been shown to be a predictor of better prognosis in kidney 
(Lidgren, Hedberg et al. 2005). This probably reflects the balance between 
HIF1 and HIF2, which is unique for this VHL mutated tumour. The 
majority of studies in lung cancer show high HIF-1 is associated with worse 
prognosis (Giatromanolaki, Koukourakis et al. 2001; Giatromanolaki,  
CHAPTER 1  60 
 
Koukourakis et al. 2003; Kim, Rabbani et al. 2005) but there is an exception 
(Volm and Koomagi 2000). These differences may relate to the difficulties 
in reliability of HIF immunostaining of paraffin embedded tissues due to its 
inherent instability; the possible differential effects of HIF-1 and HIF-2 
(Raval, Lau et al. 2005); or the variability of activity of HIF depending on 
its microenvironment (Blouw, Song et al. 2003). 
 
Furthermore, overexpression of HIF in tumours has been shown to correlate 
with resistance to drug, radiation and hormone treatment as well as 
photodynamic therapy (Koukourakis, Giatromanolaki et al. 2001; 
Koukourakis, Giatromanolaki et al. 2002; Generali, Berruti et al. 2006; 
Koukourakis, Bentzen et al. 2006). 
 
1.4.4  HIF-1 vs. HIF-2 - Differential Function 
As discussed previously, HIF-1 and HIF-2 share 48% sequence homology, 
however their significant differences in their C-terminal sequences may 
explain why many RNAi knockdown studies have shown differential 
expression profiles of known hypoxia inducible genes by HIF-1 and HIF-2 
(Sowter, Raval et al. 2003). A recent study on human RCC (VHL-defective) 
cell lines demonstrated that differential activation of HIF-1 or HIF-2 
pathways has non-equivalent or even opposing effects on gene expression 
and experimental (mouse model) tumour growth (Raval, Lau et al. 2005). 
HIF-2 was shown to have positive effects on tumour growth, in this model, 
whilst HIF-1 had negative effects. Consistent with these observed effects on 
tumour growth were differential effects on the expression of specific genes 
with putative pro- and antitumourigenic effects. In particular, HIF-1 
positively regulated BNIP3 but had no effect on CyclinD1, TGF-alpha and 
VEGF, whereas HIF-2 negatively regulated BNIP3 and positively regulated 
CyclinD1, TGF-alpha and VEGF.  
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Little is known of the effects of HIF-1 and HIF-2 on the overall survival of 
patients with primary Clear-Cell Renal Cell Carcinoma (CC-RCC), how 
their expression relates to their primary target gene products or the 
pathological characteristics of the tumour (Fuhrman grade, Stage or Tumour 
Size). It is also not known whether expression of HIF-1, within these VHL 
deficient tumours, is concomitant with expression of HIF-2, and whether co-
expression (if present) leads to the preservation of the previously 
demonstrated HIF-isoform specific target gene products.  
 
From the previous literature, there is a suggestion that HIF-1alpha is a 
prognostic marker of better overall survival in primary CC-RCC. Analysis 
of HIF-1 protein expression by western blot on 92 CC-RCCs was shown to 
be an independent prognostic factor (Lidgren, Hedberg et al. 2005), 
although subsequent Tissue Microarray (TMA) analysis only showed a 
trend towards HIF-1 being of prognostic significance (p=0.055) (Lidgren, 
Hedberg et al. 2006). CAIX, one of HIF-1’s principal target genes, has a 
more convincing case for prognostic significance, with high CAIX 
expression being an independent predictor of better prognosis (Bui, Visapaa 
et al. 2004).    
 
There is a lack of data for the prognostic significance of HIF-2, although for 
HIF-2 dominant target gene products, GLUT-1 is positively correlated with 
worse tumour grade and poorer survival in breast, rectal and oral SCC 
tumours, although nothing has been shown in CC-RCC (Cooper, Sarioglu et 
al. 2003; Kunkel, Reichert et al. 2003; Vleugel, Greijer et al. 2005), and 
cyclin D1 is preferentially expressed in lower grade renal tumours 
(Hedberg, Davoodi et al. 1999). 
 
1.5  Angiogenesis 
Angiogenesis is the development of new branching vessels from existing 
vasculature, and has long been established as a hallmark of cancer and  
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essential for tumour development and metastasis. There are a number of 
different mechanisms involved including vessel sprouting and bridge 
formation, although both are dependent on endothelial cell migration and 
proliferation. Circulating endothelial progenitor cells derived from bone 
marrow are also recruited to sites of active angiogenesis by tumour-derived 
growth factors such as vascular endothelial growth factor (VEGF). 
(Carmeliet and Jain 2000) 
 
Other mechanisms that are involved in vascularisation of tumours include: 
intussusception, where interstitial tissue columns expand and insert into the 
lumen of an existing vessel; vasculogenesis, where major vessels are formed 
de novo from mesenchymal tissues (as in the developing embryo); vascular 
co-option, where tumour cells invade surrounding tissue and make use of 
existing blood vessels; and vascular mimicry, where vascular channels are 
formed without the presence of endothelial channels, by the tumour cells 
themselves organizing into a lumen. (Folberg and Maniotis 2004)  
 
Angiogenic vessels show several differences from mature vessels. They 
have a disorganized and irregular structure, the interactions between cells, 
endothelial cells and pericytes are altered and the blood flow is abnormal. 
This is in contrast to the organized, regular structure and normal blood flow 
seen in mature vessels. The angiogenic vessels are leaky, aiding 
extracellular matrix signalling and metabolism, as well as contributing to 
tumour cell invasion and metastasis.  
 
For angiogenesis to occur there must be a switch from the physiologic 
quintessence of endothelial cells to an ‘angiogenic’ phenotype. This may be 
a result of metabolic stresses such as hypoxia, acidosis, inflammation or 
immune-cell activation. Genetic mutations may also affect the equilibrium 
of the factors directly with oncogenes and tumour suppressor genes (such as 
H-ras, HER2 and p53) (Bergers and Benjamin 2003).  
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Tumour angiogenesis can be assessed by using an anti-endothelial-cell 
antibody to identify tumour vasculature. Microvessel density (MVD) can 
then be measured either as an average of counts over a number of randomly 
selected areas, termed the mean MVD; quantified in the densest areas of 
neovascularisation, termed hotspots; or the whole tumour section can be 
assessed (not hotspots), quantified as high, medium or low, termed Vessel 
Visual Index (VVI).  
 
Marked angiogenesis is a key pathological feature of primary CC-RCC, due 
in part to the pre-mentioned VHL mutation and activation of the hypoxic 
pathway. The increasing array of non-cytokine based novel biological 
therapies that are available for the treatment of metastatic disease are 
primarily targeted against the vascular axis. However, angiogenesis is not 
the only determinant factor in tumour perfusion, as the composition and 
integrity of the proteoglycan basement membrane and the extent of pericyte 
coverage of the vessels are also known to be important factors in this regard.  
 
The role of angiogenesis in CC-RCC tumourigenesis is well established, 
however, the role of these vessels in determining factors such as overall 
survival and tumour grade are yet to be fully elucidated. The majority of 
published papers support the intuitive direct relationship with angiogenesis, 
overall survival and Fuhrman grade (Anastassiou, Duensing et al. 1996; 
Rioux-Leclercq, Epstein et al. 2001; Sabo, Boltenko et al. 2001; Schraml, 
Struckmann et al. 2002; Imao, Egawa et al. 2004), however a few have 
demonstrated an inverse relationship (Yoshino, Kato et al. 1995; Nativ, 
Sabo et al. 1998; Joo, Oh et al. 2004), whilst others have failed to show any 
relationship (MacLennan and Bostwick 1995; Minardi, Lucarini et al. 
2005). The earliest literature on these matters, were dogged by problems in 
methodology, namely the use of Von Williebrand Factor (vWF) as an 
endothelial marker. The discovery of CD31, CD34 and CD105 (endogolin) 
as endothelial markers, has rectified this satisfactorily and there have been a  
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number of reviews on MVD that summarize the growing body of evidence 
supporting MVD as a method to assess angiogenesis in urological 
malignancies, but that also show the pitfalls (Folkman 2004) (Kerbel and 
Folkman 2002) (Hlatky, Hahnfeldt et al. 2002) (Fox and Harris 2004). 
Additionally, it has recently been demonstrated that there is a strong 
positive correlation between these markers in CC-RCC, although a 
differential CD31/CD34 profile, namely CD34
+/CD31
-, has been shown to 
be indicative of an immature CC-RCC tumour vasculature and a worse 
prognosis in primary CC-RCC (Yao, Qian et al. 2007). 
 
1.6  VEGF 
VEGF is probably the most important HIF dependent target gene, and has a 
major role in hypoxia induced angiogenesis. It has been shown to have a 
significant role in many tumours including breast, colon, kidney, bladder, 
prostate, as well as many others. 
 
It is a growth factor that is important in blood and vessels development due 
to its role in regulation of angioblast (endothelial progenitors) specification 
and vasculogenesis (Weinstein 1999). It exists in four forms of variable 
amino acid length, that each exerts a different mitogenic effect on vascular 
endothelial cells or tumour cells to promote angiogenesis. VEGF modulates 
its effects through its tyrosine kinase receptors VEGF receptor 1 (also 
known as fms-like tyrosine kinase receptor 1, or Flt-1) and VEGF receptor 2 
(or kinase insert domain receptor, a product of the KDR gene). Further 
VEGF signal transduction occurs via other receptors including neuropilin-1 
and -2.  
 
In hypoxia, activation of HIF directly increases the VEGF transcript (Liu, 
Cox et al. 1995) (Forsythe, Jiang et al. 1996) and its receptor Flt-1 (Gerber, 
Condorelli et al. 1997), as well as enhancing the stability of VEGF mRNA 
via HIF activation of HuR protein, which binds to the VEGF 3’UTR (Levy,  
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Chung et al. 1998). VEGF translation is protected from the general 
reduction in protein synthesis secondary to hypoxia, by the presence of an 
internal ribosomal entry site within the 5’UTR of VEGF. This allows 
efficient cap-independent translation to be maintained (Stein, Itin et al. 
1998).  
 
Because HIF regulates many angiogenic pathways besides VEGF, (Harris 
2002) the strong associations with VEGF may reflect these additional 
pathways, (Na, Wu et al. 2003) and may explain why VEGF has a better 
validated role in RCC compared to other urologic malignancies. (Edgren, 
Lennernas et al. 1999) VEGF is not expressed in renal tissue from patients 
with benign renal disease, but is increased in patients with conventional, 
papillary and chromophobe RCC (Jacobsen, Grankvist et al. 2004), 
particularly in clear cell tumours. High VEGF expression is a predictor of 
unfavourable survival and its expression level is proportional to both 
malignant potential of a tumour and its advancement, suggesting that it has a 
role as a prognostic marker in RCC.  
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1.7  MicroRNA 
1.7.1  Introduction 
As previously discussed, hypoxic stress decreases oxidative phosphorylation 
with subsequent reduction of ATP production and protein translation. 
However, the mechanisms involved in this selective transcriptional 
upregulation of certain proteins in a background of decreased ATP, is yet to 
be fully elucidated. There is some evidence to suggest that there is variable 
dependency of certain transcripts for the translational machinery, such as the 
internal ribosomal entry site within the 5’UTR of VEGF (Stein, Itin et al. 
1998; Wek, Jiang et al. 2006). Another possibility, however, is that hypoxia 
induced microRNAs are regulating this specific protein translation. This is 
of particular interest in ccRCC with its known defect in the hypoxic 
pathway, and is explored later in this thesis. 
 
1.7.2  Background 
MicroRNAs are a recently discovered novel class of gene regulators. They 
are small (18-22 nucleotides) non-coding, single-stranded RNA. Despite 
their essential role in biological and disease processes, the first microRNA 
(lin-4) was only identified in 1993 (Lee, Feinbaum et al. 1993; Wightman, 
Ha et al. 1993). This remained an isolated example until 2000 when 
microRNA let-7 was also discovered in C. elegans, and found to be highly 
conserved in a wide range of organisms (Reinhart, Slack et al. 2000). Since 
this time, thousands of microRNAs have been cloned and characterised 
from a diverse range of organisms. There are currently 474 experimentally 
confirmed microRNAs listed in the miRBase database (Motzer, Hutson et 
al. 2007), representing approximately 1% of the human transcriptome. 
However, computational approaches suggest that there may be over 1000 
microRNAs in humans (Bentwich, Avniel et al. 2005; Berezikov, Guryev et 
al. 2005).  
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1.7.3  Synthesis 
Most human microRNAs are encoded within introns of mRNAs, although 
others are located within exons or the 3’ UTR of mRNA (Rodriguez, 
Griffiths-Jones et al. 2004). MicroRNAs are transcribed as 5’- capped large 
polyadenylated transcripts (pri-microRNA). About 40% of all human 
microRNAs are co-transcribed as clusters of up to eight microRNAs per pri-
microRNA. The pri-microRNA is cleaved within the nucleus by a 
microprocessor complex (including the RNaseIII-nuclease, Drosha), 
resulting in 60-70 nucleotide hairpin structure (pre-microRNA) which 
encodes for a single microRNA sequence. Exportin5 exports the pre-
microRNA from the nucleus into the cytoplasm where it undergoes further 
cleavage by another RNaseIII-nuclease, Dicer. This forms a short-lived 
asymmetric duplex which is subsequently loaded into the miRISC complex 
in which Argonaut (Ago) proteins are the key effector molecules, producing 
an active mature microRNA (Schwarz, Hutvagner et al. 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 – MicroRNA Processing 
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1.7.4  Function 
The primary function of microRNA is inhibition of protein translation. Their 
precise function though is complex and yet to be fully understood, although 
the outcome of mature microRNAs appears to be largely dependent upon 
the degree of complimentarity between the microRNA and its target gene. 
In plants, microRNAs have near perfect homology to their targets and 
binding results in degradation of mRNA in a process similar to the siRNA 
pathway. Some human microRNAs are believed to act via a similar 
mechanism, however, the majority only have limited sequence homology to 
their targets, (commonly just a 6-8 nucleotide ‘seed’ region at the 5’ end), 
and inhibit protein translation without mRNA degradation (Yekta, Shih et 
al. 2004). The precise nature of this inhibition remains unclear, however 
suggested mechanisms include the prevention of elongation or degradation 
of developing translation products (Olsen and Ambros 1999); microRNA-
miRISC sequestration in P-bodies, away from the translational machinery 
(Liu, Valencia-Sanchez et al. 2005); prevention of translational factors 
recognising the 5’ cap (Pillai, Bhattacharyya et al. 2005); or removal of the 
5’ cap (Sen and Blau 2005). It is thought that each microRNA may target 
many hundreds of mRNAs, possibly accounting for 10-30% of all human 
genes (John, Enright et al. 2004; Gregory and Shiekhattar 2005). 
 
1.7.5  MicroRNA and Cancer 
1.7.5.1   Importance 
MicroRNAs have been shown to be vital in many cellular processes 
including development, differentiation, apoptosis and proliferation (Bartel 
2004; Harfe 2005). Mutations within, or abnormal expression of 
microRNAs can allow them to dysregulate these processes and function 
indirectly as oncogenes or tumour-suppressor genes (Esquela-Kerscher and 
Slack 2006). Furthermore, several microRNAs have also been proven to 
interact with known oncogenic or tumour-suppressor pathways. (See Table 
1.3)  
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1.7.5.2   Diagnosis 
The use of microRNAs in differentiating specific tumour types and their 
level of differentiation is an interesting area of future development. For all 
cancer types investigated so far, specific microRNA profiles have been 
identified. These include colon (Michael, SM et al. 2003), breast (Iorio, 
Ferracin et al. 2005), leukaemia (Calin, Ferracin et al. 2005), liver 
(Murakami, Yasuda et al. 2006), lung (Yanaihara, Caplen et al. 2006), 
pancreatic (Volinia, Calin et al. 2006) and thyroid cancer (He, Jazdzewski et 
al. 2005).  
 
Two sizeable studies have looked at microRNA profiles from a large 
number of different tumour types and both have been able to accurately 
cluster their microRNA expression profiles according to their 
developmental lineage and state of differentiation, and to a far greater 
accuracy than compared to standard gene expression arrays (Lu, Getz et al. 
2005; Volinia, Calin et al. 2006). Interestingly these studies have shown that 
global expression of microRNA is reduced in tumours compared to normal 
tissue, although individual microRNAs may be up or down regulated, and 
appears to be quite tumour specific. This general downregulation may be a 
reflection of the state of cellular differentiation, and there is some evidence 
to show that microRNA expression in poorly differentiated tumours is 
similar to early embryonic developmental (Song and Tuan 2006).  
 
It may be possible in the future to use microRNA profiles as a diagnostic 
tool from clinical samples such as blood, urine, serum or biopsy specimens. 
This is clearly an exciting possibility in Urology where accurate biological 
classification of small kidney lesions, early diagnosis or surveillance 
bladder cancer and Prostate Specific Antigen (PSA) testing in prostate 
cancer are ongoing difficulties. 
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1.7.5.3   Prognosis 
In lung cancer high expression of miR-155 has been shown to correlate with 
poor prognosis (Yanaihara, Caplen et al. 2006). A decreased level of let-7 
has also been demonstrated to be an independent prognostic factor in a 
separate study in lung cancer from Japan (Takamizawa, Konishi et al. 
2004). The significance of decreased let-7 may be due to its known 
inhibition of the Ras oncogene (Johnson, Grosshans et al. 2005). 
 
There have been no studies yet analysing microRNAs and their prognostic 
significance in urological malignancies, although clearly this could be 
beneficial if it were to highlight patients that would benefit from more 
aggressive treatment. 
 
1.7.5.4   Treatment 
Although patient safety and drug efficacy clearly need to be established, it 
may be possible to inhibit many oncogenic genes via modified microRNA 
molecules. Developments of potential delivery systems are in an early stage 
(e.g. anti-microRNA oligonucleotides (Weiler, Hunziker et al. 2006), locked 
nucleic acid oligonucleotides (Orom, Kauppinen et al. 2006), and 
antagomirs (Krutzfeldt, Rajewsky et al. 2005)), although it is possible that 
microRNAs may offer a novel method of gene manipulation in a clinical 
setting, in the near future. 
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MicroRNA  Cancer Association  Reference  MicroRNA 
Function 
miR-15a, miR-16 
Negatively regulates 
anti-apoptotic gene 
BCL2 
(Cimmino, Calin et al. 2005)  Tumour-
Suppressor 
Let-7 family 
members 
Negatively regulates the 
RAS oncogene + 
Decreased in Lung Ca 
(Eder and Scherr 2005; 
Johnson, Grosshans et al. 
2005; Akao, Nakagawa et al. 
2006) 
Tumour-
Suppressor 
miR-143, miR-145 
Decreased in Colon, 
Breast, Prostate, 
Cervical, and Lymphoid 
Ca 
(Michael, SM et al. 2003; 
Akao, Nakagawa et al. 
2006) 
Tumour-
Suppressor 
miR-17-92 cluster 
(17-5, 17-3, 18a, 
19a, 20a, 19b-1, 92-
1) 
Negatively regulates the 
MYC oncogene 
(Hayashita, Osada et al. 
2005; Tagawa, Karube et al. 
2007) 
Tumour-
Suppressor 
miR-155  Increased in Breast Ca 
and lymphomas 
(Iorio, Ferracin et al. 2005; 
Kluiver, Haralambieva et al. 
2006; Tam and Dahlberg 
2006) 
Pro-
Tumourigenic 
miR-21 
Anti-apoptotic + 
Upregulated in 
Glioblastomas and 
Breast Ca 
 
(Chan, Krichevsky et al. 
2005; Iorio, Ferracin et al. 
2005; Si, Zhu et al. 2007) 
Pro-
Tumourigenic 
Table 1.3 - MicroRNA with known cancer associations 
 
1.7.6  MicroRNA and Hypoxia 
A recent paper by Kulshreshtha et al. has assessed the effect of hypoxia on 
tumour cell lines, and analysed for differential effects, based on HIF 
induction (Kulshreshtha, Ferracin et al. 2007). They showed that there is a 
reliable hypoxic signature of nine microRNAs (termed hypoxia regulated 
microRNAs, HRMs), and that HIF induced this increased expression under 
hypoxia. (See Table 1.4) 
 
Interestingly HIF-1 was shown to have a more dominant effect on miR-24 
and miR-181, whilst HIF-2 had a greater effect on miR-26. Although the 
potential targets or functions of these microRNAs are unknown, it adds 
weight to the idea that HIF-1 and HIF-2 have differential functions. 
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Hypoxia Regulated  
MicroRNA 
HIF Isoform  
Induction 
   
23   
24  HIF-1 
26  HIF-2 
27   
103   
107   
181  HIF-1 
210   
213   
Table 1.4 – Experimentally confirmed Hypoxia regulated MicroRNAs 
 
1.7.7  MicroRNA and VHL 
Very little is known about the relationship between microRNA expression 
and VHL, although it could be hypothesised that microRNA specific to 
VHL binds to the 3’ or 5’ ends of VHL mRNA blocking its translation. In 
addition the regulation of transcription factor (e.g. HIF) stability by VHL in 
normoxia and hypoxia could potentially result in differences in microRNA 
expression. (See Figure 1.9) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 - Hypothesised interaction of microRNA with VHL and hypoxia 
pathway 
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1.8  Hypotheses 
The differential regulation of HIF dependent target genes demonstrated in-
vivo is a reflection of the biology within clinical ccRCC. Furthermore, high 
expression of the pro-tumourigenic HIF2 isoform within tumours is 
associated with poor prognosis, whilst high expression of HIF1 is associated 
with better prognosis. This differential expression of the HIF isoforms is 
regulated by microRNA.   
 
1.9  Primary topics addressed in this thesis 
Initial focus is given to the assessment and analysis of all nephrectomies 
performed at our institution, with the aim to understand the nature of 
changing incidence and clinico-pathological variables of renal tumours. The 
establishment of a clinical database has enabled this assessment and 
analysis, as well as allowing an appropriate cohort of tumours to be selected 
for further investigation.   
 
Further chapters, using a series of patient derived primary tumours from the 
clinical database, investigate the observed differential effects of HIF-1 and 
HIF-2 on HIF target gene expression and tumour growth, in the VHL 
defective cell lines and the in-vivo mouse model, demonstrated by Raval et 
al. (Raval, Lau et al. 2005).  
 
Assessment of expression of HIF isoforms attempts to establish what the 
relationship is between HIF-1 and HIF-2 and whether these correlate to 
clinico-pathological variables, including patient survival. Furthermore, this 
thesis assesses the utility of HIF isoforms and their target gene products, as 
prognostic markers in primary ccRCC. 
 
Further work in this thesis explores the role of microRNA in a VHL 
defective tumour model, and examines whether specific microRNAs are  
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differentially regulated according to the functionality of the hypoxic 
pathway, and HIF isoform expression.    
 
Therefore, the research in this thesis is primarily directed at determining the 
nature of the HIF pathway, its regulation and thus its role in renal tumours. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 2: 
Materials and Methods  
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Chapter 2:  Material and Methods 
 
2.1  Clinico-Pathological Variables in RCC 
2.1.1  Relational database 
Clinical, pathology and outcome data on all urological malignancies within 
Oxford since 1983, available in electronic format, was amalgamated, 
structured and cross-referenced into a single relational database called 
CRUD© (Charlesworth Research Uro-Oncology Database), using 
Filemaker Pro v6 (Apple Inc, USA) (See Figure 2.1). Prospective data was 
initiated in October 2006 for all urological malignancies in Oxford with 
electronic links to the Pathology archives (Pathology Department, Oxford 
Radcliffe Hospitals NHS Trust), the Oxford Cancer Intelligence Unit 
(OCIU), and the Infoflex data system for collection of all urology patients 
discussed at the weekly Multi-Disciplinary Team Meeting (Chameleon 
Information Management Services Ltd, UK). This has organised and pooled 
a large quantity of retrospective data and has enabled extensive prospective 
data collection on all urological patients in Oxford, with minimal data entry.  
 
Further electronic links are in development with the Oncology Department 
(Oxford Radcliffe Hospitals NHS Trust) databases for chemotherapy, 
radiotherapy, clinical trials, the Radiology department (Oxford Radcliffe 
Hospitals NHS Trust) databases for diagnostic imaging, as well as blood 
result indices from the Haematology and Biochemistry departments. (See 
Figure 2.2)  
 
CRUD© has also developed into an expanding collaborative resource for all 
urological research in Oxford, and has associated modules that monitor all 
urological tissue, blood and urine specimen collection, storage and use. 
Furthermore there are additional modules in development that assist the 
Urological cancer surgeons in collecting British Association of Urological 
Surgeons (BAUS) Cancer Registry compatible data.  
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Figure 2.1 – Charlesworth Research Uro-Oncology Database - Homepage 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 – Diagrammatic representation of CRUD© links to other IT 
systems  
 
2.1.2  Retrospective Kidney Cancer Data Collection 
All kidney cancer pathology samples have been logged within the archives 
of the Pathology Department (Oxford Radcliffe Hospitals NHS Trust) since 
1983. The pathology reports were available in electronic format and were 
downloaded into the relational database CRUD©. The inclusion criteria for  
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the subsequent data analysis within this thesis were all nephrectomies 
(Radical, Partial or Laparoscopic) with documented cancer involvement, 
reported by the Pathology department from January 1983 to May 2007. 
Pathological data from these cases was assessed within the CRUD© system 
to extract pathological tissue diagnosis, tumour T-stage (reclassified 
according to 2002 criteria), Fuhrman grade, and maximum tumour diameter 
(cm).  
 
Each tumour was related to available clinical data (age, sex and date of 
operation) and patient survival data from the Oxford Cancer Intelligence 
Unit (OCIU), within the CRUD© system. Survival data from the OCIU 
originates from death certificates, with death from Kidney Cancer being 
classified as being 1a. The death status of patients was classified by Alive / 
Dead, Date of death, Cause of Death (Kidney Cancer / Other).  
 
2.1.3  Ethical Approval 
Prior to amassing data retrospectively and establishing protocols for 
prospective data collection we ascertained proof of our ethical approval 
from the Central Office for Research Ethics Committees (main REC – 
Oxfordshire). We also had to fulfil the Caldicott regulations for data 
protection, anonymisation, proliferation and security when establishing our 
database relationships (Health; Health 1997). 
 
2.1.4  Tissue Collection 
In Oxford we have excellent procedures for the collection of fresh kidney 
and bladder cancer tissue as well as blood and urine samples for research 
purposes and have many hundreds of samples within the urology liquid 
nitrogen bio-banks. With the introduction of the Human Tissue Act we have 
had a responsibility to ensure that we meet these rigorous criteria. 
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2.1.5  Human Tissue Act 2004 
In 2001 the Chief Medical Officer issued recommendations to the 
government regarding the removal, storage and use of human organs and 
tissue from post-mortem examination (Health 2004). Subsequently the 
government introduced legislation in November 2004 regulating these 
matters (Human Tissue Act 2004) (Health 2004). The Human Tissue 
Authority (a DOH ‘arm’s length body’) was also established to oversee and 
regulate the institutional collection and retention of human tissues, with 
each institution required to apply for an HTA licence by April 2006 
(Authority 2006). Under the University of Oxford licence, collection of each 
sample has to have specific ethical approval and patient consent. The 
storage of the sample has to be in an approved bio-bank in an anonymous 
manner. The eventual use of samples can only be within the boundaries of 
the original ethical approval and all sample usage needs to be auditable 
retrospectively. 
 
We have developed a system that fulfils all of these criteria with minimal 
data-entry at the point of tissue collection or utilisation. (See Figure 3.3) 
 
 
 
 
 
 
 
Figure 2.3 – CRUD© Urology Tissue – Data Entry Page 
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2.1.6  Project Tracking 
To protect the patients on whom we collect data and tissue we have 
established strict mechanisms to only allow access to the data/tissue to 
personnel that fulfil the criteria of their and our regional ethics committees. 
We have done this by only allowing access to the data/tissue to 
researchers/doctors with unique project tracking numbers. These are only 
issued upon receipt of a completed project tracking request form, which has 
to pass through the CRUD© Committee and satisfy the essential ethical and 
legal criteria. The additional benefit of this is that the use of all data and 
tissue is tracked in real-time and fully auditable retrospectively. 
 
To maintain Oxford’s ethical and legal obligations in this regard we have 
developed a module adjoined to CRUD© that anonymises, tracks and 
protects all of our tissue collections and storage. (See Figure 2.4) 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 – CRUD© Urology Tissue – Project Tracking page 
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2.1.7  Data Analysis 
Statistical analysis and graphs were generated using Graphpad Prism v4.03.  
The log-rank test was used to perform a univariate analysis for survival and 
the survival curves were estimated by Kaplan-Meier method. P values were 
considered statistically significant when P<0.05. 
 
 
 
2.2  Assessment of Angiogenesis and Hypoxia in CC-RCC prognosis 
2.2.1  Introduction 
Clear cell RCC specimens were stained using Immunohistochemistry (IHC) 
for HIF-1 and HIF-2 antibodies, as well as some of their target genes 
highlighted as having differential regulation by the Raval et al.. Tissue 
MicroArray technology was used to increase the throughput and number of 
samples analysed. Clinical and pathological data was collected from the 
CRUD© relational database and cross-analysed with the IHC data. 
  
2.2.2  Selection Criteria 
Selection criteria for inclusion into the tissue microarrays (TMAs) used in 
this study were all registered primary nephrectomies for clear cell renal 
carcinoma from 1983 to 1999, performed at the Churchill or John Radcliffe 
Hospitals, Oxford. The first TMA to be constructed, TA38, included all 
primary CC-RCC sourced from the pathology archives from 1983 to 1993, 
and included a total of 93 cases. The second TMA, TA71 used all primary 
CC-RCCs from 1994-1999 and included 77 cases. There were no records 
available for 1994 due to a lack of pathology data, and therefore no samples 
have been included into the TMAs from that year. 
 
2.2.3  Ethical Approval 
Use of all samples was under the guidelines laid out by the Human Tissue 
Authority (HTA) and with the approval of the Central Office of Research  
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Ethics Committee (COREC) covering the samples at the Churchill Hospital 
and John Radcliffe Hospital, Oxford, UK. 
 
2.2.4  Data Storage 
The aforementioned relational database ‘Charlesworth Research Uro-
Oncology Database’ (CRUD©) was used to collect, organise and store the 
clinical and pathological data on the tumour samples contained within the 
TMAs. 
 
2.2.5  Pathology Validation 
2.2.5.1   Tumour Tissue Diagnosis 
The archived formalin-fixed and paraffin-embedded blocks of tumour tissue 
were retrieved from the pathology stores and 5µm sections, from all cases, 
were cut on a microtome (Anglia Scientific, model 0325). These were 
reassessed by a Consultant Pathologist using Haematoxylin & Eosin (H&E) 
stained whole tumour sections at x100 magnification, to confirm the tissue 
diagnosis of clear cell renal cancer.  
 
2.2.5.2   Fuhrman grade  
Fuhrman grade was also re-assessed according to Fuhrman et al (Fuhrman, 
Lasky et al. 1982), with the grade assigned being the highest grade present 
in each tumour..  
 
2.2.5.3   Tumour Stage 
Using the original pathology reports, all cases were re-staged using the 2002 
TNM classification (Cancer 2002). It is however worth noting that the renal 
sinus was commonly not assessed in 1983-1999 and therefore many stage 1 
and 2 tumours could be under-staged according to modern criteria. Also, 
nodal and metastatic status was indeterminate for many of the samples due 
to the pathological data available; therefore it was not included in the T- 
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staging for analysis. Maximum tumour diameter (cm) was also obtained 
from the pathology report at the same time as re-staging. 
 
2.2.6  Patient Survival 
Patient outcome was assessed via the Oxford Cancer Intelligence Unit 
archives, which monitors cancer deaths by analysis of death certificate. 
Outcome data was classified as alive, deceased (non-cancer), deceased 
(other cancer – not kidney) or deceased (kidney cancer). The patients 
categorized as alive were cross-referenced against the NHS hospital 
appointments system to confirm date last seen. 
 
2.2.7  Tissue Microarray Construction 
Two tissue cores, each 1.5 mm in diameter were taken from 
morphologically representative regions of the paraffin blocks, excluding 
areas of necrosis or non-tumoural tissue. The tissue cores were then inserted 
into recipient paraffin blocks to construct the two TMAs (TA38 and TA71), 
using a tissue arrayer (Beecher Instruments). Tissue cores of non-neoplastic 
renal tissue from ten cases were also included in the microarray as controls. 
The construction of the TMAs was performed by Dr Leticia Campo, 
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, 
Oxford. 
 
 
 
 
 
 
 
 
Figures 2.5a and 2.5b – Example of TMA block (left) and TMA 
4micrometer slice stained with H&E.  
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2.2.8  Immunohistochemistry 
The TMAs were sectioned into 4 micrometre slices, deparaffinised in 
citroclear and rehydrated in a series of gradient ethanol, then rinsed in 
distilled water. Endogenous peroxidase activity was quenched with 0.3% 
hydrogen peroxidase for 5 min. 
 
Please refer to Table 2.1 for the antibody source, the antigen retrieval 
method and the dilutions used. The mouse and rabbit anti-human primary 
antibodies were probed with their respective secondary antibodies using the 
Chemate polymer Envision-HRP kit. For the goat anti-sheep secondary 
antibody (Abcam, Ely, UK) a dilution of 1:200 for 30 minutes at room 
temperature was used to label the LDH5 primary antibody and rabbit anti-
goat (DAKO, Ely, UK) was used at a dilution of 1:200 for 30 minutes at 
room temperature for Oct-4. 
 
The DAB signal was generated in all cases by mixing the chromagen 
substrate with the appropriate buffer provided for in the Chemate kit and 
applying the resultant solution onto the tissue sections for between 2-5 
minutes dependant upon the epitope load within the tumour. All sections 
were subsequently counterstained with haematoxylin. 
 
As will be discussed later in the results section of chapter 4, the antigenicity 
of HIF-1 and HIF-2 subjectively appeared to be decreased on the older 
tumour samples during scoring. All TMA slides used for HIF-1 or HIF-2 
were cut freshly off the arrays and stained at the same time to minimise any 
other variable that would alter staining intensities. 
 
All immunohistochemistry performed on the TMAs was performed by Dr 
Helen Turley and Dr Leticia Campo, Weatherall Institute of Molecular 
Medicine, John Radcliffe Hospital, Oxford. 
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Antibody  Source  Antigen Retrieval  Antibody Dilution 
HIF-1 alpha 
Mouse monoclonal, Clone 
54 BD Biosciences 
Pharmingen 
1 mM EDTA 
pH 8.0 
1:100 
8 hours 
4 degrees 
 
HIF-2 alpha  Mouse monoclonal, 
EP190; Oxford University 
1 mM EDTA 
pH 8.0 
Neat application 
8 hours 
4 degrees 
 
BNIP3  Mouse monoclonal, 
ANa40; Sigma, UK 
Sodium Citrate 
pH 6.0 
1:200 
2 hours 
Room temperature. 
CAIX 
Mouse monoclonal, M75; 
Albert Einstein CM, New 
York, USA 
Sodium Citrate 
pH 6.0 
1:50 
2 hours 
Room temperature. 
CD31  Mouse monoclonal, 
JC70A; Oxford University. 
Sodium Citrate 
pH 6.0 
1:5 
30 minutes 
Room temperature. 
Cyclin D1  Mouse monoclonal, DCS-
6; Dako, Ely, UK 
Tris-EDTA 
pH 9.0 
1:50 
1 hour 
Room temperature. 
GLUT-1  Rabbit polyclonal, DAKO, 
UK 
Sodium Citrate 
pH 6.0 
1:200 
1 hour 
Room temperature. 
LDH5  Sheep polyclonal; Abcam, 
UK  No antigen retrieval 
1:400 
2 hours 
Room temperature. 
Oct-4  Goat polyclonal (C-20); 
Santa-Cruz, USA 
Sodium Citrate 
pH 6.0 
1:200 
2 hours 
Room temperature. 
VEGF  Rabbit monoclonal, SP28; 
Abcam, UK 
Sodium Citrate 
pH 6.0 
Pre-diluted 
10 minutes 
Room temperature. 
Table 2.1 - Primary antibodies used on TA38 and TA71. 
 
2.2.9  TMA Scoring 
The TMAs were reviewed by two people and a consensus determined. A 
score was obtained for each stain using all optical fields, in the relevant cell 
compartment (see Table 3.2). Staining was scored according to the intensity 
and percentage of tumour cells stained. The intensity was scored 0 (no 
staining); 1 (mild); 2 (moderate) and 3 (strong staining). Percentage staining  
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was scored as 0 (no staining); 1 (1-10%); 2 (11-50%); 3 (51-90%) and 4 
(91-100%). An expression ‘Histoscore’ was then calculated for analysis 
using the product of the two scores, giving a resultant score of 0-12. 
 
2.2.10  Angiogenesis Quantification   
To quantify angiogenesis we used the Vessel Visualisation Index (VVI) at 
x200 magnification, as it is known to positively correlated with Microvessel 
Density (MVD) and Chalkley count and has recently been shown to 
correlate positively between TMA staining and whole tumour section 
staining for CD31 (Yao, Qian et al. 2007). VVI was determined by looking 
at each core as a whole (not vascular hotspots) and angiogenesis was scored 
as ‘high’, ‘moderate’ and ‘low’. Subsequently, for statistical purposes, this 
was further delineated into either of two scores: 1= high vessel tumours and 
0 = moderate or low vessel tumours. 
 
Stain  Cell Compartment Scoring 
(used in analysis) 
HIF-1 alpha  Nucleus 
HIF-2 alpha  Nucleus 
BNIP3  Cytoplasm 
CAIX  Membrane 
Cyclin D1  Nucleus 
GLUT-1  Membrane 
LDH5  Nucleus 
Oct-4  Cytoplasm 
VEGF  Cytoplasm 
Table 2.2 - Cell compartment scored for each stain 
 
2.2.11  Statistical Analyses 
Statistical analysis and graphs were generated using Graphpad Prism v4.03 
and the Stata package release 8.1 (Stata Corporation, Texas, USA).  
 
For non-continuous analysis high / low cut-offs were determined by 
calculating the median expression histoscore (See Table 4.2, Chapter 4). 
Contingency tables were analysed using the Pearson's chi-squared test. 
Correlation between continuous variables was assessed by Spearman Rank  
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correlation. The log-rank test was used to perform a univariate analysis for 
survival and the survival curves were estimated by Kaplan-Meier method. 
Prognostic factors for survival were evaluated in multivariate analyses by 
Cox proportional hazards regression. P values were considered statistically 
significant when P<0.05. 
 
 
2.3  MicroRNA in Renal Clear Cell Carcinoma and its relationship 
to the Von-Hippel Lindau tumour-suppressor gene and hypoxia 
pathway 
 
2.3.1  Cell Lines 
A panel of clear cell renal cancer cells lines were chosen for the in-vitro 
section of this work. All cell lines were ordered via Cancer Research UK 
Central Cell Services, London, UK. 768-O and RCC4 cell lines were 
selected for consistency with the previous in-vitro and mouse model work as 
discussed in the introduction to this thesis (Raval, Lau et al. 2005). A further 
cell line, UMRC2 (a gift from EA Maher) was also used and was available 
from CRUK central cell services. All cell lines originate from a clear cell 
RCCs with an inherent non-functional VHL gene, and were available with a 
paired identical cell line with stably transfected functional wild-type VHL 
gene. Therefore six cell lines were used for my experiments, 3 x identical 
pairs with only their VHL status as a variable. 
 
Stable VHL transfection and HIF-1 / HIF-2 expression has been validated 
for these cell lines 768-0 (Maxwell, Wiesener et al. 1999; Raval, Lau et al. 
2005; Yuen, Cockman et al. 2007), RCC4 (Maxwell, Wiesener et al. 1999; 
Raval, Lau et al. 2005; Yuen, Cockman et al. 2007) and UMRC2 (Maxwell, 
Wiesener et al. 1999; Jung, Isaacs et al. 2003). Furthermore UMRC2 and 
RCC4 cells have been shown to express both HIF-1alpha and HIF-2alpha, 
while 768-0 cells only express HIF-2alpha (Maxwell, Wiesener et al. 1999). 
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HIF subunits were constitutively expressed in normoxia (21% Oxygen) as 
well as hypoxia (0.1% Oxygen) in the VHL mutant cells (UMRC2/VHL-ve, 
RCC4/VHL-ve and 768-0/VHL-ve), but were only detectable in hypoxia in 
the VHL functional cells (UMRC2/VHL-ve, RCC4/VHL+ve and 768-
0/VHL+ve) (Maxwell, Wiesener et al. 1999; Raval, Lau et al. 2005; Yuen, 
Cockman et al. 2007). 
 
2.3.2  Cell Culture 
All the cell lines were maintained using Dulbecco’s Modified Eagle’s 
Medium (DMEM) in polystyrene dishes (Becton Dickinson, UK) and flasks 
with vented caps (Falcon, UK), supplemented with 10% heat-inactivated 
fetal calf serum (FCS) (Globepharm, UK), 2mM L-glutamine, 50 IU/ml 
penicillin and 50 µg/ml streptomycin. The 768-O, RCC4 and UMRC2 cells 
were stably transfected with VHL, as previously described (Clifford, 
Cockman et al. 2001; Zatyka, da Silva et al. 2002; Craven, Hanrahan et al. 
2006), and maintained with 1mg/ml of G418 (GIBCO-BRL). 
 
Cells were cultured in a humidified atmosphere of 5% CO2 at 37 degrees 
Celsius. They were passaged by washing in phosphate buffered saline (PBS 
– 150mM NaCl and 150mM NaH2PO4), detached with trypsin-EDTA 
solution (4mg/ml trypsin, 0.2mM EDTA in PBS) (GIBCO-BRL), and re-
plated to the required density (dependent upon experiment). 
 
All cells were routinely screened for mycoplasma infection by CRUK 
central cell services, as per laboratory protocol. For cryopreservation, 
cultured cells were harvested, spun down (GS-6R Centrifuge, Beckman 
Instruments, UK), re-suspended in 20% dimethyl sulphoxide (DMSO) 80% 
FCS, and aliquoted into cryovials. These aliquots were then slowly cooled 
to minus 80 overnight, prior to placement in liquid nitrogen for storage. For 
revival, cells were quickly thawed with pre-warmed medium, and re-plated. 
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For experimental purposes, when cells reached 80% confluence within the 
Falcon flasks, they were passaged, diluted by 1 in 10 with medium and 
plated onto 10cm polystyrene tissue culture dishes (Falcon, Becton 
Dickinson, UK). Cells were then allowed to rest in normoxia for 8 hours 
prior to incubation in normoxia (21% Oxygen) or in hypoxia (0.1% 
Oxygen) in a Galaxy R CO2 incubator (RS Biotech, UK) for 16 hours. 
 
2.3.3  RNA Extraction 
For RNA extraction, cells were removed from the incubator after 16 hours 
and cell culture medium removed. Cells were lysed directly in the culture 
dish by addition of 1ml of TRI reagent (Sigma-Aldrich, UK) and passed 
several times through a pipette. After five minutes, to allow complete 
dissociation of the nucleoprotein complexes, 0.2ml of chloroform was 
added, and the sample was vortexed (Labinco Vortex, Netherlands) for 15 
seconds. After storage for 15 minutes at room temperature, the sample was 
centrifuged at 12 000g for 15 minutes at 4 degrees Celsius (Mikro 22R, 
Hettrich Zentrifugen, Netherlands). The RNA containing colourless upper 
aqueous phase was then removed, placed in a fresh tube and the RNA 
precipitated using 0.5ml of isopropanol. After a further centrifugation at 
12000g for 8 minutes (4 degrees Celsius), the liquid isopropanol was 
removed and the precipitated RNA pellet briefly allowed to air-dry. It was 
then resuspended in 0.2ml RNAse free-water (Qiagen, UK), and quantified 
using a ND-100 Spectrophotometer (NanoDrop Technologies, USA) at 
extinction co-efficient of 40, and a 2100 Bioanalyser (Agilent, UK). RNA 
samples were subsequently stored at minus 80 degree Celsius until further 
use. 
 
2.3.4  MicroRNA isolation 
MicroRNA was isolated from the RNA samples using the RNeasy Mini Kit 
(Qiagen, UK). A starting concentration of 45 micrograms of RNA was used 
(optimum starting concentration as per Qiagen protocol).  
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The RNA was initially placed onto RNAeasy – mini spin column (Qiagen, 
UK) with 80% ethanol, and centrifuged at 8000g for 15 seconds. The 
concentration of ethanol used precipitated out large RNA which 
subsequently collected on the glass-fibre filter of the column, but was 
insufficient to precipitate out small RNA (including microRNA), which 
passed through the filter and was collected in a separate container. The total 
RNA excluding microRNA remaining on the column filter was then 
subjected to a series of washes, using RW1 and RPE buffers (supplied in 
RNeasy Mini Kit, Qiagen, UK). 30 microlitres of pre-heated RNAase free 
water was subsequently passed through the column to re-dissolve the 
precipitated RNA (excluding the microRNA).    
 
980µl of 100% ethanol was added to the flow-through (containing the 
microRNA) from the first RNeasy mini spin column. This ethanol 
concentration was sufficient for microRNA precipitation and succeeding 
addition to the RNAeasy – mini elute column (Qiagen, UK), resulted in the 
trapping of the precipitated microRNA onto the finer glass fibre filters of 
this column. Washes of the precipitated microRNA were performed using 
0.5ml RPE buffer and 80% ethanol, each centrifuged through the column at 
8000g for 15 seconds.  
 
2.3.5  MicroRNA MicroArrays 
2.3.5.1   Introduction 
The microRNA microarrays (µRNA™ Microarray, University of Oxford) 
used were made available on a collaborative basis with Dr C Lawrie, 
Nuffield Department of Clinical Laboratory Sciences, University of Oxford. 
Each chip contained microRNA sense probes for all known human 
microRNAs, as well as control ‘spike-in’ sequences, for scanning and image 
analysis normalisations.  
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2.3.5.2   Hybridisation 
The microarrays and lifterslips (M-series 25x42, VWR, UK) were prepared 
prior to hybridisation via cleaning with 100% ethanol; rapidly dried using 
high pressure nitrogen; and incubated at 65 degrees Celsius for 20 minutes 
in pre-hybridisation solution (35mls 20x SSC (3M NaCl, 0.3M Sodium 
Citrate) (Ambion, UK); 20mls Bovine Serum Albumin solution (BSA 
100mg/ml) (Sigma-Aldrich, UK); 2mls 10% SDS (Sodium Dodecyl Sulfate, 
Ambion, UK)). 
 
Two micrograms of purified microRNA was used from each one of the 
original paired cell line samples, and diluted into a volume of 13.5µl with 
RNase-free water (Qiagen, UK). The MicroRNA samples were used as a 
template to produce complimentary microRNA by reverse transcription 
(RT), using Superscript II kit (Invitrogen, UK). A mastermix of the 
superscript components including spike-in controls (Invitrogen,UK) were 
added prior to labelling each pair of the cell line with 2µl Cy3 or Cy5 RT 
primers (MicroRNA labelling kit, Genesphere, UK), whereupon the samples 
were incubated for 10 minutes at 65°C. The paired samples, Cy3 or Cy5 
respectively, were mixed together and added to 25µl of hybridisation buffer 
(MicroRNA labelling kit, Genesphere, UK), and loaded onto the prepared 
microRNA microarrays contained within sterilised hybridisation chambers 
(Cambio, UK). The chambers were then incubated at 52°C for 16 hours, to 
allow the tagged complimentary microRNA sequences to hybridise to the 
sense probes on the microarray. 
 
Following hybridisation, the microarrays were removed from the chambers 
and washed in filter-sterilised 2 x SSC, 0.2% SDS (Ambion, UK) with 
shaking for 15 minutes at 42°C. Further washes were then performed with 2 
x SCC and 0.2 x SSC, with shaking for 15 minutes each, before the slides 
were rapidly dried using nitrogen as before.   
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A mastermix containing 2.5µl of Cy3 and Cy5 3DNA capture reagents 
(MicroRNA labelling kit, Genesphere, UK) with hybridisation buffer was 
then prepared for each chip, and loaded carefully onto each using fresh 
lifterslips. This was performed in limited light conditions due to the light 
sensitivity of the capture reagents. The microarrays were then incubated for 
a further 4 hours at 62°C, followed by washing and drying as previously 
described. 
 
2.3.5.3   MicroArray Scanning 
The microarrays were subsequently scanned using a ScanArray SA4000 
(GSI, Lumonics, Packard / Perkin Elmer, USA). Focusing and PMT gain 
setting were automatically adjusted via the preset optimised protocol. 
Resultant Cy3 and Cy5 images were saved and transferred to the image 
analysis software as high resolution ‘.tiff’ files. 
 
2.3.5.4   Quality control 
The threshold of expression intensity varied for each cell line, due to cell 
line variability in microRNA expression as well as experimental efficiency 
of microRNA binding to the array. Therefore subjective assessment of array 
quality was made after scanning, with only high quality arrays being 
included in the analysis. (See Figure 2.6). Microarrays were repeated as 
necessary to complete three biological replicates per cell line comparison. 
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Figure 2.6 – Cell line RCC4 (VHL+ve Cy3: VHL-ve Cy5).Typical example 
of MicroRNA Expression MicroArray quality. 
 
2.3.5.5   Image Analysis 
Image analysis was performed using the software package, BlueFuse for 
MicroArrays version 3.3 (BlueGnome, UK).  
 
The individual Cy3 and Cy5 images were imported into the software, as 
well as the microarray ‘.gal’ file, containing an overlay grid for the location 
of all microRNAs on the array. The .gal file overlay was performed 
automatically by the software but was also manually checked prior to image 
quantification. A protocol was written in the software to exclude low 
intensity and background hybridisation, although all arrays were manually  
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checked to confirm correct inclusion / exclusion criteria. (See Figure 2.7). 
Figures 2.8 and 2.9 demonstrate individual Cy3 and Cy5 images with 
composite image (combined Cy3 and Cy5). Cy3 and Cy5 pixel intensities 
within each hybridised spot were quantified by the BlueFuse software. 
 
Subsequent post-processing (also performed by the BlueFuse software) 
resulted in image global lowess normalisation based on controls and 
hybridised microRNAs. Weighted medians were automatically generated 
for the microRNA quadruplicates and fused to produce a single Excel 
spreadsheet (Windows Microsoft Office 2003) of all expressed microRNAs 
on the array. 
 
2.3.5.6   Data Analysis 
Further data manipulation and analysis was performed using GeneSpring v7 
(Agilent, USA), GraphPad Prism v4.03 and Filemaker Pro v7 (Apple Inc, 
USA).   
 
 
 
 
 
 
 
 
 
Figure 2.7 - MicroRNA Expression MicroArray with overlying .gal file in 
BlueFuse software (BlueGnome, UK), used to identify each expressed 
‘spot’ of microRNA. 
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Figure 2.8 - Demonstration of individual pixel intensity analysis of Cy3 and 
Cy5 together with Cy5/Cy3 composite. 
 
 
 
 
 
 
 
 
 
Figure 2.9 - Three examples of variable Cy3 / Cy5 hybridisation: Image 1 
(left) shows high Cy3 intensity giving an overall green composite image; 
Image 2 (centre) shows high Cy5 intensity giving an overall red composite 
image; Image 3 (right) shows saturated Cy3 and Cy5 from a ‘spike-in’ 
control. 
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2.3.6  Polymerase Chain Reaction (PCR) 
2.3.6.1   Introduction 
Quantitative analysis of mature microRNA was performed using two-step 
real-time polymerase chain reaction (RT-PCR) (Taqman MicroRNA 
Assays, Applied Biosystems).  
 
2.3.6.2   Reverse Transcription 
In the reverse transcription (RT) step, cDNA was reverse transcribed from 
the RNA samples using specific microRNA looped RT-primers (miR-23a 
RT-primer and RNU6B RT-primer, Taqman MicroRNA Assays, Applied 
Biosystems) and the reagents from the Taqman MicroRNA Reverse 
Transcription kit, as described in the manufacturer’s instruction protocol. 
 
2.3.6.3   PCR 
In the PCR step, PCR products were amplified from the cDNA samples 
(from the RT step) using the Taqman MicroRNA Assay together with the 
Taqman Universal PCR Master Mix, as described in the manufacturer’s 
instruction protocol. This was performed using a LightCycler 480 Real-
Time PCR system (Roche Applied Science). The resultant data was 
transferred to Excel (Windows Microsoft Office 2003) and GraphPad Prism 
v4.03 for analysis.  
  
 
 
 
 
 
 
 
 
 
 
Chapter 3: 
Renal Cancer Prognosis and  
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CHAPTER 3:  Renal Cancer Prognosis and Clinico-Pathological 
Variables  
 
3.1 Introduction 
Kidney Cancer is a common condition in the UK accounting for 2% of all 
cancers. Treatment has changed very little over the past few decades for 
primary locally confined disease, however patient survival has improved 
significantly over this time. The mechanisms of this observed change are yet 
to be fully understood although tumour size at diagnosis, surgical caseload 
or a change in disease distribution may be important. 
 
3.2 Results 
3.2.1  Clinico-Pathological and Survival Analysis of all cancer 
nephrectomies in Oxford, January 1983 to May 2007 
A total of 750 cancer nephrectomies were performed at the John Radcliffe 
or Churchill Hospitals, from January 1983 to May 2007. 664 (89%) were for 
Renal Cell Carcinoma (RCC) (See Table 3.1 and 3.2), with the remaining 
11% mainly Transitional cell Carcinoma (TCC). The 1, 5 and 10-year 
survival of patients post-nephrectomy for RCC was 89%, 73% and 63% 
respectively (See Figure 3.2 and Table 3.4).  
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Table 3.1 – Age, Sex and Survival Distribution of all cancer nephrectomies 
(all tumour types) in Oxford, January 1983 to May 2007. 
 
 
1983 –  
1986 
1987 – 
1990 
1991 – 
1994 
1995 – 
1998 
1999 – 
2002 
2003 –  
2007  Total 
Number of RCCs          
Chromophobe  0 0 1 0 6 9  16 
Clear Cell  23 29 67 86  141  191  537 
Collecting Duct  1 0 0 2 2 0  5 
Papillary  2 3 5  20  20  28  78 
Sarcomatoid  2 3 5 2 1 1  14 
Other  0 0 1 0 4 9  14 
          
Total  28 35 79  110  174  238  664 
          
% of total RCCs          
Chromophobe  0.0 0.0 1.3 0.0 3.4 3.8  2.4 
Clear Cell  82.1 82.9 84.8 78.2 81.0 80.3  80.9 
Collecting Duct  3.6 0.0 0.0 1.8 1.1 0.0  0.8 
Papillary  7.1 8.6 6.3  18.2  11.5  11.8  11.7 
Sarcomatoid  7.1 8.6 6.3 1.8 0.6 0.4  2.1 
Other  0.0 0.0 1.3 0.0 2.3 3.8  2.1 
Table 3.2 – Distribution of Pathology Tissue Diagnoses of all cancer 
nephrectomies for RCC in Oxford, January 1983 to May 2007. 
All Kidney Tumour Types   
Cancer 
Nephrectomies in 
Oxford 
   n  % 
Year of Nephrectomy      
      Range    1983-2007 
     
Total No of Cases     750 
     
Sex      
      Male    490 65 
      Female    260 35 
     
Age  (years)      
      Median    64 
10-91        Range   
     
End State      
      Alive    437 58 
      Death from Kidney Cancer    191 25 
      Death from other cause    122 17  
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Figure 3.1 – Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies (all tumour types) in Oxford Jan 1983 to May 
2007. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford January 1983 to May 2007. 
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All RCCs   
Cancer 
Nephrectomies in 
Oxford 
      
      
   n  % 
Year of Nephrectomy      
      Range    1983-2007 
     
Total No of Cases     664 
     
Sex      
      Male    429 65 
      Female    235 35 
     
Age  (years)      
      Median    64 
18-87        Range   
     
Tumour T Stage      
      1a    116 17 
      1b    115 17 
      2    84 13 
      3a    103 15 
      3b    233 35 
      3c    6 1 
      4    5 1 
     
Fuhrman Grade      
      1    89 14 
      2    297 48 
      3    179 29 
      4    57 9 
     
Max Tumour Diameter (cm)      
      <5    222 35 
      5-7    128 20 
      7-10    168 26 
      >10    121 19 
     
End State      
      Alive    397 60 
      Death from Kidney Cancer    167 25 
      Death from other cause    100 15 
 
Table 3.3 – Clinico-Pathological Variables of all cancer nephrectomies for 
RCC in Oxford, January 1983 to May 2007. 
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Table 3.4 – 1, 5 and 10-year survival patients undergoing nephrectomy for 
all tumour types of kidney cancer and just RCC, in Oxford January 1983 to 
May 2007. 
 
3.2.2  Renal Cancer Survival – Trends over Time 
To assess how prognosis from kidney cancer has changed over time, all 
RCC nephrectomies were divided into six cohorts of four inclusive years, 
based upon their date of operation. Figure 3.3 below shows a clear change in 
kidney cancer specific survival over the past 24 years (logrank test 
p<0.0001), with 1-year survival improving from 74% (1983-1986) to 95% 
(2003-2007), and 10-year survival changing from 17% (1983-1986) to 70% 
(1995-1998) (See Table 3.5). Further analyses later in this chapter focus on 
the nephrectomies from 2002 to 2007 as survival during this period is 
relatively stable. 
 
 
Cancer Nephrectomies 1983-2007 
In Oxford 
   
  All Types  Just RCC 
   
1 year survival  88%  89% 
   
5 year survival  72%  73% 
    
10 year survival  62%  63%  
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Figure 3.3 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford January 1983 to May 2007, 
split into 4-year cohorts. 
 
 
 Year  of  Nephrectomy 
        
 
1983 – 
1986 
1987 – 
1990 
1991 – 
1994 
1995 – 
1998 
1999 – 
2002 
2003 – 
2007 
        
1  year  survival  74% 76% 84% 89% 90% 95% 
        
5 year survival  42%  58%  69%  75%  73%  N/A 
        
10 year survival  17%  47%  59%  70%  N/A  N/A 
 
Table 3.5 - 1, 5 and 10-year survival patients undergoing nephrectomy for 
RCC, in Oxford January 1983 to May 2007, split in 4-year cohorts.  
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3.2.3  Cancer Nephrectomy Caseload 
The number of RCC nephrectomies performed each year has increased by a 
factor of 10 over the past 24 years, and has a significant association with 4-
year survival from kidney cancer (Chi-squared p<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 – Number of Nephrectomies for RCC in Oxford per year, 
January 1983 to May 2007. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 - Number of Nephrectomies for RCC in Oxford per 4 years vs. 4 
year Survival, January 1983 to May 2007. (Bars on left represent number of 
Nephrectomies per year / Bars on right represent % 4-year survival) 
Nephrectomy Case-Load over Time
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3.2.4 Operative  Mortality 
For all cancer nephrectomies, operative mortality as measured by death 
within 30 days of operation is 2.3%, which has not changed significantly 
over the past 24 years. 
 
 
 
 
 
 
 
 
Figure 3.6 – Percentage 30-day mortality following Nephrectomy for RCC 
in Oxford per 4-year cohort, January 1983 to May 2007. 
 
Table 3.6 – Number and percentage 30-day mortality following 
Nephrectomy for RCC in Oxford per 4-year cohort, January 1983 to May 
2007. 
 
 
 
 
 
 
 
 
1983-
1986
1987-
1990
1991-
1994
1995-
1998
1999-
2002
2003-
2007 
Total 
No of Nephrectomies  28  36  91  125  192  278  750 
30  Day  mortality  1 2 1 4 3 6  17 
%  Operative  3.6 5.6 1.1 3.2 1.6 2.2 2.3 
Change in 30-day Mortality over time
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Variation of Age at Nephrectomy over Time
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3.2.5  Age at Operation 
The mean age at operation for all cancer nephrectomies has not changed 
significantly over the past 24 years. (See Figure 3.7) 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 – Mean age at Nephrectomy for RCC in Oxford per 4-year 
cohort, January 1983 to May 2007. 
 
3.2.6 Fuhrman  Grade 
Nuclear Fuhrman grade shows clear univariate survival significance 
(logrank test p<0.0001), with Fuhrman grade 4 tumours having the shortest 
survival (See Figure 3.8). Survival per Fuhrman grade category is not 
significantly altered when the analysis is focused upon the most recent 
nephrectomies (2002-2007) compared to the earlier nephrectomies (1983-
2001) (See Figure 3.9 a & b). Fuhrman grade 3 and 4 tumours continue to 
have similar survival with 5-year survival approximately 20%, and 65% 
respectively. In comparison, Fuhrman grade 1 and 2 tumours have 
significantly improved survival with 5-year survival rates improving from 
approximately 85% to 95% and 100% respectively (See Figure 3.9b). The 
distribution of Fuhrman grade per year has not changed significantly over 
this time (See Figure 3.10). 
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Figure 3.8 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford January 1983 to May 2007, 
split into 4 Fuhrman Grade categories. 
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Figure 3.9a - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford January 1983 to 2001, split into 
4 Fuhrman Grade categories.  
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Figure 3.9b - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford January 2002 to May 2007, 
split into 4 Fuhrman Grade categories. 
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Figure 3.10 – Percentage Distribution of Fuhrman Grade of RCC 
Nephrectomy specimen, January 1983 to May 2007. 
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3.2.7 Tumour  T-stage 
Tumour T-stage is an important univariate prognostic factor (logrank test 
p<0.0001). Analysis of the prognostic significance of stage after 2002, 
demonstrates consistent 5-year survival for T3 and T4 tumours, but an 
improved survival in T2 tumours from 85% to 97%, and an improved 
survival in T1 tumours from 93% to 100% (See Figure 3.12 a & b). The 
distribution of T-stage has not changed over time (See Figure 3.13). 
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Figure 3.11 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford, January 1983 to May 2007, 
split into 4 Tumour Stage categories. 
 
 
 
 
 
 
  
CHAPTER 3  110 
 
Stage vs Kidney Cancer Specific Death
(1983-2001)
0 5 10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
Stage 1a 1b (n=124)
Stage 2 (n=48)
Stage 3a 3b 3c (n=200)
Stage 4 (n=1)
Survival (Years)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
 
Figure 3.12a - Kaplan Meier Survival Curve (Death from Kidney Cancer) 
of all cancer nephrectomies for RCC in Oxford, 1983 to 2001, split into 4 
Tumour Stage categories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12b - Kaplan Meier Survival Curve (Death from Kidney Cancer) 
of all cancer nephrectomies for RCC in Oxford, January 2002 to May 2007, 
split into 4 Tumour Stage categories. 
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Figure 3.13 – Percentage Distribution of Tumour Stage of RCC 
Nephrectomy specimen, January 1983 to May 2007. 
 
3.2.8  GS Product Score 
A simple continuous variable of the product of Fuhrman grade and T-stage 
for RCCs was generated for prognostic significance, and termed GS product 
score. This was subsequently divided into four cohorts to aid interpretation. 
This demonstrated increased prognostic significance compared to Fuhrman 
grade or T-stage alone. Patients with a GS product score of 4 or less showed 
a 5-year survival of 100%, whilst increased score showed progressively 
poorer prognosis (See Figure 3.14 and Table 3.7). 
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Figure 3.14 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford, January 2002 to May 2007, 
split into 4 cohorts of Grade and Stage Product. 
 
 GS  Product  Score 
        
 <4  6  8-9  >12 
        
1 year survival  100%  95%  93%  62% 
        
5 year survival  100%  86%  54%  20% 
 
Table 3.7 - 1 and 5-year survival of patients undergoing nephrectomy for 
RCC, in Oxford, January 2002 to May 2007, split in 4 cohorts of Grade and 
Stage Product. 
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Table 3.8 - Distribution of patients to each 4 cohorts of Grade and Stage 
Product. 
 
3.2.9  Tumour Size - Trend over time 
Mean tumour size has not changed over the past 24 years (See Figure 3.15). 
Further analysis of tumour size was performed by assessing the percentage 
of cases per centimetre. Figures 3.16 and 3.17 show the distribution of 
tumour sizes in 2 cohorts (1983-1998 and 1999-2007) with a subtle shift to 
smaller tumours in later years. To investigate this further the size of tumour 
was sub-categorised into three similarly sized cohorts (A: <6cm, B: 6-8cm 
and C: >8cm) tumours. Figure 4.18 shows a 5 fold increase in the number of 
size A tumours, with a corresponding decrease in size B tumours. Of note is 
that there is no change in size C tumours over the past 24 years. This sub-
categorisation of maximum tumour diameter is a significant univariate 
prognostic marker (logrank test p<0.0001), with size C tumours having the 
poorest survival (See Figure 3.19). 
GS Product Score Stage x Grade Number of 
Cases 
<4  1x1 12 
  1x2 70 
  1x3 22 
  1x4 1 
  2x1 3 
  2x2 15 
  3x1 4 
  4x1 0 
    
6  2x3 15 
  3x2 51 
    
8-9  2x4 1 
  4x2 1 
  3x3 64 
    
>12  3x4 22 
  4x3 1 
 4x4  2  
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Nephrectomies: 1983-1998 (n=237)
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Figure 3.15 – Mean Maximum Tumour Diameter vs. Year of Nephrectomy, 
of all cancer nephrectomies for RCC in Oxford, January 1983 to May 2007. 
 
 
 
 
 
 
 
 
Figure 3.16 – Percentage 
distribution of Maximum Tumour 
Diameter, of all cancer 
nephrectomies for RCC in 
Oxford, January 1983 to 
December 1998. 
 
 
Figure 3.17 – Percentage 
distribution of Maximum Tumour 
Diameter, of all cancer 
nephrectomies for RCC in 
Oxford, January 1999 to May 
2007. 
 
 
Variation of Tumour Size at Nephrectomy over time
1
9
8
3
 
S
i
z
e
1
9
8
4
 
S
i
z
e
1
9
8
5
 
S
i
z
e
1
9
8
6
 
S
i
z
e
1
9
8
7
 
S
i
z
e
1
9
8
8
 
S
i
z
e
1
9
8
9
 
S
i
z
e
1
9
9
0
 
S
i
z
e
1
9
9
1
 
S
i
z
e
1
9
9
2
 
S
i
z
e
1
9
9
3
 
S
i
z
e
1
9
9
4
 
S
i
z
e
1
9
9
5
 
S
i
z
e
1
9
9
6
 
S
i
z
e
1
9
9
7
 
S
i
z
e
1
9
9
8
 
S
i
z
e
1
9
9
9
 
S
i
z
e
2
0
0
0
 
S
i
z
e
2
0
0
1
 
S
i
z
e
2
0
0
2
 
S
i
z
e
2
0
0
3
 
S
i
z
e
2
0
0
4
 
S
i
z
e
2
0
0
5
 
S
i
z
e
2
0
0
6
 
S
i
z
e
2
0
0
7
 
S
i
z
e 0
1
2
3
4
5
6
7
8
9
10
11
M
a
x
i
m
u
m
 
T
u
m
o
u
r
 
D
i
a
m
e
t
e
r
 
(
c
m
)
M
e
a
n
 
&
 
S
E
M
Nephrectomies: 1999-2007 (n=405)
0
-
1
1
-
2
2
-
3
3
-
4
4
-
5
5
-
6
6
-
7
7
-
8
8
-
9
9
-
1
0
1
0
-
1
1
1
1
-
1
2
1
2
-
1
3
1
3
-
1
4
1
4
-
1
5
1
5
-
1
6
1
6
-
1
7
1
7
-
1
8
1
8
-
1
9
>
1
9 0
2
4
6
8
10
12
14
Tumour Size
P
e
r
c
e
n
t
a
g
e
 
o
f
 
N
e
p
h
r
e
c
t
o
m
i
e
s 
CHAPTER 3  115 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 – Percentage distribution of Maximum Tumour Diameter per  
4-year cohort according to size sub-category (A-C), of all cancer 
nephrectomies for RCC in Oxford, January 1999 to May 2007. 
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Figure 3.19 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all cancer nephrectomies for RCC in Oxford, January 2002 to May 2007, 
split into 3 cohorts of Size sub-category (A-C). 
Change in Cancer Nephrectomy Tumour Size over time
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3.3 Discussion 
3.3.1 Survival 
Overall patient survival in Oxford compares well to national data, with 5-
year survival rates nationally being 42% (Office for National Statistics, 
2007) whilst in Oxford they are 73%. This was certainly not the case 20 
years ago when the 5-year survival in Oxford was only 43%. The trend 
towards improved survival over the years has been progressive, with 
gradually increasing survival seen for every four year cohort analysed. The 
cause of this significant change is likely to be multifactorial, and the 
breakdown of caseload, Fuhrman grade, T-stage, tumour size and operative 
mortality goes some way to explain this phenomenon.  
 
3.3.2 Incidence 
The number of nephrectomies performed has risen by a factor of 10, which 
correlates to the improving survival. It is established that high throughput 
cancer centres with experienced Urological surgeons performing large 
numbers of operations is beneficial to patients (National Institute for 
Clinical Excellence 2002) and therefore it is one of the many changes in 
provision of cancer services within the UK in recent years. It is unclear 
whether this alone can result in the dramatic increase demonstrated, 
although it is likely to be a contributing factor.  
 
3.3.3 Operative  Mortality 
The stable rate in operative mortality over the past 24 years partially negates 
the idea that the rise in cancer nephrectomy caseload is the sole reason for 
the changes in survival. It would be expected that if the change was only 
due to improved operative experience, then a similar trend would be seen in 
death within 30 days of operation. However, the concentration of cancer 
operations within cancer centres in the UK and the development of co-
ordinated multi-disciplinary teams for the selection and management of 
operative cases may well have an influence on outcome.  
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 3.3.4  Age at Operation 
It could be hypothesised that in an aging population, that the age of patients 
at the time of their nephrectomy has changed over the past 24 years. This 
was not supported by the analysis which demonstrated that there has been 
no change over this time. This suggests that age is a less important risk 
factor in RCC that previously thought.  
 
3.3.5 Fuhrman  Grade 
The observation that Fuhrman grade is a prognostic marker in RCC is not 
surprising, and is well documented in the literature. However, the improved 
survival in grade 1 and 2 tumours in the past 20 years, with unchanged 
grade 3 and 4, suggests that the nature of disease may have changed, and the 
increased incidence is generating lower grade tumours that hence have 
improved survival. Alternatively it may be that the increased specialisation 
of reporting pathologists has resulted in a change in distribution of grade. 
 
3.3.6 T-stage 
It is also unsurprising that tumour T-stage is a prognostic marker in RCC, 
however, the same shift towards improved survival for low stage tumours in 
recent years, is demonstrated in T-stage as it was in tumour grade. The 
compounding factor with T-stage is the change in the TNM classification in 
2002. The inclusion of the renal sinus into pathological assessment has 
meant that many T2 and some T1 tumours prior to 2002 would now be 
classified as T3. This goes some way to explain the demonstrated improved 
prognosis for T1 and T2 tumours. It is possible that the previously assumed 
non-invasive tumours (that were in actual fact invading the renal sinus), 
have been shifted into the T3 category, where the decreased survival of this 
cohort represents them better. 
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3.3.7  GS Product Score 
The combination of grade and stage to produce a single prognostic factor is 
not unique. The SSIGN prognostic algorithm developed by the Mayo clinic 
has much greater prognostic power, based on grade, stage, necrosis and 
patient performance status (Frank, Blute et al. 2002). However, the simple 
product of grade and stage may prove to be of value clinically, particularly 
with regards follow up post nephrectomy. Many clinicians would discharge 
a low grade and low stage tumours early, however if a patient had a T2 
tumour with Fuhrman grade 3, early discharge may not be warranted as their 
5-year survival is only 85%. Furthermore, added confidence is gained in the 
knowledge that even in the presence of vascular invasion (T3), if Fuhrman 
grade was 1 then early discharge and patient reassurance may be possible. 
 
Additionally the cohort of patients with GS Product Score of >12, do 
dramatically worse than the other cohorts. This may highlight the category 
of patients to include in future research trials, as they are the patients most 
likely to progress.   
 
3.3.8 Size 
With the increased quality and quantity of diagnostic imaging available, a 
greater number of incidental (pre-symptomatic) tumours are being detected 
(Chow, Devesa et al. 1999). The true significance of these tumours is 
currently a hotly debated subject in Urology. It is difficult to know what the 
true clinical course of these tumours would be if left undetected, and 
whether the removal of all of them is warranted.  
 
It is also not clear cut whether the increased detection of these renal tumours 
is solely due to improved diagnostic imaging or whether there is a natural 
pattern of increasing incidence of RCC from another source. The increase in 
detection rates has also highlighted locally advanced and metastatic renal 
tumours, which does suggest that the increased detection of localised  
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tumours is not the sole reason for the observed improvement in patient 
survival. 
 
My data shows that there has been no overall decrease in the mean size of 
tumour at time of nephrectomy. However, on further evaluation of tumour 
size by sub-division into three size cohorts (A: <6cm, B: 6-8cm and C: 
>8cm) it is clear that there has been a significant increase in the number of 
tumours <6cm and a corresponding decrease in tumours 6-8cm. This may 
relate to the trend of progressively improving survival, as the 5-year 
survival for size A tumours is 95% whilst for size B tumours it is 85%. 
However, this change would only seem to account for a 10% increase in 5-
year survival, and does not completely explain the changes documented. 
 
The consistent proportion of size C tumours undergoing nephrectomy is 
interesting and seems to go against the changes seen in tumours ≤8cm. A 
possible explanation may be a change in referral patterns coinciding with a 
shift towards earlier detection of renal masses. Within Oxford there has 
been a subjective increase in the number of difficult cases involving large 
tumours referred from other centres, although I have no data to analyse this 
objectively. An alternative possibility is that the cohort of large tumours 
represents an alternative tumour biology that grows rapidly, avoiding early 
detection and curative nephrectomy. Later in this thesis I explore this 
possibility further with analysis of the relationship of tumour size with 
markers of angiogenesis and the hypoxic pathway, including the HIF 
isoforms. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 4: 
Angiogenesis and Hypoxia in Primary 
Clear Cell Renal Carcinoma and its 
effect on patient prognosis  
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CHAPTER 4:  Angiogenesis and Hypoxia in Primary Clear Cell Renal 
Carcinoma and its effect on patient prognosis 
 
4.1 Introduction 
A recent study on human RCC (VHL-defective) cell lines demonstrated that 
despite close similarities between the HIF isoforms, differential activation 
of HIF-1 or HIF-2 pathways has non-equivalent or even opposing effects on 
gene expression and experimental (mouse model) tumour growth (Raval, 
Lau et al. 2005). HIF-2 was shown to have positive effects on tumour 
growth, in this model, whilst HIF-1 had negative effects. Consistent with 
these observed effects on tumour growth were differential effects on the 
expression of specific genes with putative pro- and anti-tumourigenic 
effects. In particular, HIF-1 positively regulated BNIP3 but had no effect on 
CyclinD1, TGF-alpha and VEGF, whereas HIF-2 negatively regulated 
BNIP3 and positively regulated CyclinD1, TGF-alpha and VEGF.  
 
With a paucity of literature on the effects of both HIF-1 and HIF-2 isoforms 
as regards overall survival and primary tumour parameters such as grade 
and stage in primary ccRCC, it is not yet known whether these in-vitro and 
in-vivo observations by Raval et al. are reflective of the biology within 
clinical samples of ccRCC. Similarly, there is a lack of data as regards HIF 
target genes on the overall survival in primary ccRCC and their prognostic 
utility when combined with HIF isoforms and gross macroscopic tumour 
parameters. Indeed, there are no published studies exploring the effects of 
many of these factors in a single large cohort of patients with primary clear-
cell renal cancer (ccRCC). 
 
It is the aim of this chapter to investigate the utility of the HIF isoforms and 
their target gene products, as prognostic markers in primary ccRCC using a 
series of patient derived primary tumours. 
  
CHAPTER 4  122 
 
Distribution of Grade
1 2 3 4
0
10
20
30
40
50
60
70
80
90
Fuhrman Grade
N
u
m
b
e
r
 
o
f
 
C
a
s
e
s
4.2 Results 
4.2.1 Clinico-Pathological  Variables of CC-RCC TMAs 
Table 4.1 shows the distribution of age, sex, stage, grade, tumour size and 
patient outcome across the two TMAs used, TA38 and TA71 (Refer to 
Section 2.2.2). Figures 4.1, 4.2 and 4.3 show the graphical distribution of 
stage, grade and size of the CC-RCC specimens within the arrays. 
 
 
 
 
 
 
 
 
 
Figure 4.1 – Distribution of Stage of 
tumour specimens within TA38 and 
TA71 TMAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 – Distribution of Grade of 
tumour specimens within TA38 and 
TA71 TMAs. 
 
 
 
 
 
 
 
 
Figure 4.3 – Distribution of Size of tumour  
specimens within TA38 and TA71 TMAs. 
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Variable    TA38    TA71    TA38 + TA71 
              
              
   n  n   n  % 
Year of Nephrectomy           
      Range    1983-1993  1995-1999  1983-1999 
           
Total No of Cases on Array    93 (55%)    77 (45%)    170  100 
           
Sex            
      Male    63  51   114  68 
      Female    30  24   54  32 
           
Age  (years)            
      Median    62  64  64 
27-87        Range    36-84  27-87  
           
Tumour T Stage            
      1a    4   10    14  8 
      1b    23  10   33  20 
      2    19   5   24  14 
      3a    16  27   43  25 
      3b    29  25   54  32 
      3c    1  0   1  1 
      4    0  0   0  0 
           
Fuhrman Grade            
      1    14   5   19    11 
      2    46  39   85  51 
      3    15  23   38  23 
      4    17   9   26  15 
           
Max Tumour Diameter (cm)            
      <5    16  21   37  23 
      5-7    27  15   42  26 
      7-10    28  17   45    28 
      >10    18  21   39  24 
           
Patient Outcome            
      Alive    25  37   62  36 
      Death from Kidney Cancer    52  21   73  43 
      Death from other cause    16  19   35  21 
           
Table 4.1 – Clinico-Pathological Variables (age, sex, stage, grade, size and 
survival) of tumour specimens within TA38 and TA71 TMAs. 
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4.2.2  Distribution of Expression Histoscores 
Table 4.2 shows the number of specimens per expression histoscore for each 
of the immunohistochemical stain used on the arrays. For non-continuous 
analysis high / low cut-offs were determined by calculating the median 
expression histoscore. 
 
Table 4.2 - Distribution of Expression Histoscore. Median histoscore was 
taken as the delineation between high and low scores. Grey highlight 
represents high score, unshaded represents low score. 
 
4.2.3  Prognostic significance of the pathological characteristics of the 
tumour 
4.2.3.1   Fuhrman Grade 
In keeping with the analysis from Chapter 3, Fuhrman grade 1-3 group 
together with significantly (P<0.0001) better prognosis than patients with 
Fuhrman grade 4. For statistical analysis with other parameters, from the 
TMAs, Fuhrman grade was split into high grade (Fuhrman grade 4) and low 
grade (Fuhrman grade 1-3). (See Figures 3.8 and 4.4) 
 
 
 
 
 
Histoscore HIF1  HIF2  BNIP3  CAIX CyclinD1 GLUT1  OCT4  LDH5  VEGF 
0  25 36 100 10  16  33  3  7  16 
1 31  33 3 8 29 18  1 0 7 
2 33  37  15 6  24 22 3  4 11 
3  10  8  15 5  14 13 2  2 13 
4  25  24  14 19  23  17 25 20 54 
6  25  20  5 28 25  27 7 97  4 
8  0  1  4 8  0  2  121  36  53 
9  8  4  9  14  27  17  0  0  0 
12  5  1  1  69  7  9  2  0  1 
Total 162  164 159 167  166  158 164 166 159  
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Figure 4.4 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by Fuhrman Grade. 
 
4.2.3.2   Tumour Stage  
Increasing stage shows significantly worse prognosis (p=0.0006), (no nodal 
or metastatic data included). (See Figure 4.5) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by Tumour Stage (no nodal 
or metastatic data included). 
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4.2.3.3   Maximum Tumour Diameter (cm) 
Maximum tumour diameter was divided into three equal size cohorts, A 
(<6cm), B (6-8cm) and C (>8cm). Category A tumours have significantly 
better survival (p<0.0001) than B or C tumours. (See Figure 4.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by tumour size category. 
 
4.2.4  Time-distributed death cohorts 
For the purposes of further analyses (see later in chapter), I divided all 
patients who had died of kidney cancer into three equally sized cohorts. I 
labelled these ‘Early Death’ <11 months; ‘Intermediate Death’ 11-27 
months; and ‘Late Death’ >27 months. Naturally, these groups were 
significantly different when plotted on Kaplan-Meier survival curves. (See 
Figure 4.7 and Table 4.3) 
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Figure 4.7 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by Early (<11 months), 
Intermediate (11-27 months) and Late Death (>27 months). 
 
   Logrank Test 
p-value 
Hazard Ratio (95% 
Confidence Interval) 
Early vs  Intermediate  <0.0001***  5.4  (13-85) 
Early vs  Late  <0.0001***  5.5  (15-94) 
Intermediate vs  Late  <0.0001***  5.4  (14-84) 
Table 4.3 – Kaplan-Meier survival curve analysis (See Figure 4.7) for 
Early, Intermediate and Late Death from CC-RCC. 
 
4.2.5  Change in Kidney Cancer Specific Survival over time. 
As per the previous analysis in Chapter 3, cohorts of ‘year of nephrectomy’ 
were generated, and a similar trend was demonstrated (see comparable 
analysis Figure 3.3). Patients undergoing nephrectomy most recently (1995-
1999) had the best overall survival (10-year survival = 71%) whilst the 
patients in the earliest cohort (1983-1986) had the worst prognosis (10-year 
survival = 28%). (See Figure 4.8 and Table 4.4) 
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Figure 4.8 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split into 4-year cohorts to 
assess survival changes over time. 
 
   Logrank Test 
p-value 
Hazard Ratio (and 95% 
Confidence Intervals) 
1983-1986 vs 1995-1999  0.0018**  2.6  (1.6-7.1) 
1987-1990 vs 1995-1999  0.12   
1991-1994 vs 1995-1999  0.28   
1983-1986 vs 1987-1990  0.30   
1983-1986 vs 1991-1994  0.062   
1987-1990 vs 1991-1994  0.066   
Table 4.4 – Kaplan-Meier survival curve analysis (See Figure 4.8) for 4-
year cohort (year of Nephrectomy) 
 
4.2.6  Change in antigenicity of nuclear HIF-1 and HIF-2 over time 
As discussed during the materials and methods section of this chapter, it was 
subjectively noticed that the intensity of the HIF-1 and HIF-2 antibodies 
appeared decreased on the older tumour samples. It was found on analysis 
that the nuclear expression of HIF-1 and HIF-2 changes significantly 
depending upon the age of the paraffin block (HIF-1 alpha: p < 0.0001; 
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HIF-2 alpha: p < 0.0001, Mann-Whitney tests). This was recapitulated using 
the respective HIF alpha isoform Histoscores for each individual year 
between 1983 and 1999, for both HIF-1 alpha and HIF-2 alpha, using one-
way ANOVA analysis (Kruskal-Wallis tests). (See Figures 4.9 and 4.10). 
Therefore for all further analyses within this thesis only TA71, where HIF 
staining was stable, was used. This chronological alteration in histoscores 
was not recapitulated for any of the HIF target gene products of BNIP3, 
CAIX, CD31, cyclin D1, GLUT-1, LDH5, Oct-4 and VEGF. 
 
Variable    TA38    TA71    TA38 + TA71 
              
              
   n  n   n  % 
Nuclear HIF-1 alpha           
      High    27  46   89  55 
      Low    61  28   73  45 
           
Nuclear HIF-2 alpha            
      High    29  29   69  42 
      Low    58  48   95  58 
           
           
Table 4.5 – Distribution of HIF Expression Histoscores for each TMA and 
both combined. 
 
 
 
 
 
 
 
 
Figure 4.9 – Median HIF-1 alpha 
histoscore per age of paraffin 
block 
 
 
 
 
 
 
 
Figure 4.10 – Median HIF-2 
alpha histoscore per age of 
paraffin block 
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4.2.7  HIF-1 and HIF-2 in primary CC-RCC prognosis. 
4.2.7.1   Individual HIF effect on prognosis 
No correlation was found between the nuclear or cytoplasmic expression of 
HIF-1 and HIF-2, and individually, neither nuclear expression of HIF-1 or 
HIF-2 had any effect on overall survival. (See Figures 4.11 and 4.12). 
Interestingly, alternative survival analysis using the ‘time-distributed death 
cohorts’ revealed that nuclear expression of HIF-1 is reduced in patients that 
die within the intermediate group (11-27 months) when compared to the 
early or late death cohorts. HIF-2 shows no significant difference between 
groups (See Figures 4.13 and 4.14 & Tables 4.6 and 4.7). 
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Figure 4.11 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by HIF-1 high / low expression 
histoscore. 
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Figure 4.12 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by HIF-2 high / low expression 
histoscore. 
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Figure 4.13 – Mean HIF-1 expression histoscore per Time-distributed death 
cohort. 
HIF-1     Mann-Whitney 
p-value 
Early Death  vs  Intermediate Death  0.0054* 
Early Death  vs  Late Death  0.8597 
Intermediate Death  vs  Late Death  0.0185 
 
Table 4.6 – Mann-Whitney T-test analysis of differences between Mean 
HIF-1 expression histoscore per Time-distributed death cohort.  
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Figure 4.14 – Mean HIF-2 expression histoscore per Time-distributed death 
cohort. 
 
Table 4.7 – Mann-Whitney T-test analysis of differences between Mean 
HIF-2 expression histoscore per Time-distributed death cohort. 
 
4.2.8  HIF-1 and HIF-2 and their primary target genes in CC-RCC 
prognosis 
Seven primary target genes of HIF-1 and HIF-2 were also assessed on the 
CC-RCC TMAs and were analysed along with HIF-1 and HIF-2. They 
were: BNIP3, CAIX, CyclinD1, GLUT-1, LDH5, Oct-4 and VEGF. 
 
4.2.8.1   Correlation with HIF-1 alpha 
HIF-1 was positively correlated to CyclinD1, and showed no significant 
correlation with BNIP3, CAIX, GLUT-1, LDH5, Oct-4 or VEGF. (See 
Table 4.8). 
 
 
 
HIF-2     Mann-Whitney 
p-value 
Early Death  vs.  Intermediate Death  0.0741 
Early Death  vs.  Late Death  0.8597 
Intermediate Death  vs.  Late Death  0.0881  
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4.2.8.2   Correlation with HIF-2 alpha 
HIF-2 also was only positively correlated to CyclinD1, and showed no 
significant correlation with BNIP3, CAIX, GLUT-1, LDH5, Oct-4 or 
VEGF. (See Table 4.8). 
 
4.2.8.3   Individual Prognostic Significance of HIF Target Genes 
Taken individually none of the seven factors had any correlation on overall 
survival. (See Figures 4.15 -4.21) 
 
HIF Isoform 
Protein / Target 
Gene 
R value 
Spearman Rank 
p-value 
     
HIF-1 HIF-2   NS 
     
HIF-1  BNIP3   NS 
HIF-1  CAIX   NS 
HIF-1  CyclinD1 0.35  0.0026* 
HIF-1  GLUT1   NS 
HIF-1  LDH5   NS 
HIF-1  Oct-4   NS 
HIF-1  VEGF   NS 
     
HIF-2  BNIP3   NS 
HIF-2  CAIX   NS 
HIF-2  CyclinD1 0.38  0.0007 
HIF-2  GLUT1   NS 
HIF-2  LDH5   NS 
HIF-2  Oct-4   NS 
HIF-2  VEGF   NS 
Table 4.8 – Correlations of HIF-1 and HIF-2 to their primary target genes 
BNIP3, CAIX, CyclinD1, GLUT1, LDH5, Oct-4 and VEGF. 
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Figure 4.15 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by BNIP3 high / low 
expression histoscore. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by CAIX high / low 
expression histoscore. 
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Figure 4.17 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by CyclinD1 high / low 
expression histoscore. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by GLUT1 high / low 
expression histoscore. 
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Figure 4.19 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by LDH5 high / low 
expression histoscore. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by Oct-4 high / low 
expression histoscore. 
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Figure 4.21 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by VEGF high / low 
expression histoscore. 
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4.2.9  Fuhrman Grade in primary CC-RCC and its relationship with 
hypoxic pathway proteins, macroscopic pathological tumour 
parameters and prognosis 
As demonstrated earlier in this section, high grade (Fuhrman 4) CC-RCC 
tumours have worse overall survival compared to low grade tumours 
(Fuhrman 1-3) (p<0.0001, logrank test). (Refer to Figure 4.4). Fuhrman 
grade was significantly correlated with T-stage, Maximum Tumour 
Diameter, BNIP3 and Oct-4. (See Table 4.9).  
 
Although there was no direct correlation between Fuhrman grade and either 
of the HIF isoforms, HIF-1 and HIF-2 were both split by Fuhrman grade on 
Kaplan-Meier survival curve analysis. Nuclear expression of both HIF-1 
and HIF-2 are not able to further differentiate the high and low tumour 
grade survival curves. (See Figures 4.22 and 4.23 & Tables 4.10 and 4.11) 
 
Comparative Factor  R value  Spearman Rank 
p-value 
T-Stage 0.3555  <0.0001*** 
Maximum Tumour Diameter  0.2928  0.0002*** 
BNIP3 0.2178  0.0061** 
CyclinD1 -0.3412  <0.0001*** 
Oct-4 0.1595  0.0426* 
Table 4.9 – Correlations of Fuhrman Grade to hypoxic pathway proteins 
and macroscopic pathological tumour parameters  
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Figure 4.22 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by high / low – Fuhrman Grade / 
HIF1 expression histoscore. 
 
  Fuhrman 
Grade  HIF-1  Fuhrman 
Grade  HIF-1 
Logrank 
Test 
p-value 
Fuhrman Grade 
split by HIF-1:           
  High High  vs High  Low  0.5675 
  Low High  vs Low  Low  0.8536 
HIF-1 split by 
Fuhrman Grade:           
 High  High  vs  Low  High  0.0030** 
 High  Low  vs  Low  Low  <0.0001*** 
            
 High  High  vs  Low  Low  0.0003*** 
Table 4.10 - Kaplan-Meier survival curve analysis (See Figure 4.23) all CC-
RCC specimens in TA71, split by high / low – Fuhrman Grade / HIF1 
expression histoscore. 
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Figure 4.23 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by high / low – Fuhrman Grade / 
HIF2 expression histoscore. 
 
  Fuhrman 
Grade  HIF-2  Fuhrman 
Grade  HIF-2 
Logrank 
Test 
p-value 
Fuhrman Grade 
split by HIF-2:            
  High High  vs High  Low  0.1792 
  Low High  vs Low  Low  0.1706 
HIF-2 split by 
Fuhrman Grade:            
 High  High  vs  Low  High  0.0010*** 
 High  Low  vs  Low  Low  0.1125 
            
 High  High  vs  Low  Low  0.0091** 
Table 4.11 - Kaplan-Meier survival curve analysis (See Figure 4.23) all CC-
RCC specimens in TA71, split by high / low – Fuhrman Grade / HIF2 
expression histoscore. 
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4.2.10  Angiogenesis in primary CC-RCC and its relationship with 
hypoxic pathway proteins, Fuhrman grade, macroscopic 
pathological tumour parameters and prognosis. 
 
4.2.10.1Angiogenesis and CC-RCC Prognosis 
Angiogenesis quantified by the Vessel Visualisation Index (VVI) with 
CD31 antibody staining has prognostic significance, with high levels of 
angiogenesis conferring a good overall survival (p= 0.0003, logrank test; 
Hazard Ratio 0.3823 (95% CI: 0.2119-0.6312)). (See Figure 4.24).  
 
Angiogenesis was found to vary significantly across the three time-
distributed death cohorts (as previously defined). Significantly lower VVI 
was demonstrated in the early death cohort compared to the late death 
cohort (p= 0.0360, Mann-Whitney test). (See Figure 4.25 and Table 4.12). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by high / low Vessel Count 
(VVI). 
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Figure 4.25 - Mean Vessel Count (VVI) per Time-distributed death cohort. 
 
VVI     Mann-Whitney 
p-value 
Early Death  vs.  Intermediate Death  0.4527 
Early Death  vs.  Late Death  0.0360* 
Intermediate Death  vs.  Late Death  0.1669 
Table 4.12 – Mann-Whitney T-test analysis of differences between Mean 
Vessel Count (VVI) per Time-distributed death cohort. 
 
4.2.10.2Angiogenesis and Fuhrman Grade 
VVI split Fuhrman grade such that low grade tumours could be 
differentiated into two distinct prognostic categories. Patients with low 
grade tumours with high VVI survived significantly longer than patients 
with low grade tumours with low VVI (p=0.0017). High or low VVI in high 
grade tumours had no discriminatory survival effect. (See Figures 4.26 and 
4.27 & Table 4.13). Specific Fuhrman Grade was found to have a strong 
negative correlation with CD31+ VVI (chi-squared: p=0.0026; spearman 
rank correlation: p=0.0005 (r value -0.2941)). 
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Figure 4.26 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by high / low – Fuhrman 
Grade / Vessel Count (VVI) 
 
  Fuhrman 
Grade  Angiogenesis  Fuhrman 
Grade  Angiogenesis 
Logrank 
Test 
p-value 
Fuhrman 
Grade split 
by 
Angiogenesis: 
        
  High High  vs  High Low 0.0865 
  Low High  vs  Low Low  0.0017** 
Angiogenesis 
split by 
Fuhrman 
Grade: 
        
 High  High  vs  Low  High  0.0044** 
 High  Low  vs  Low  Low  0.0004*** 
         
 High  High  vs  Low  Low  0.4780 
Table 4.13 - Kaplan-Meier survival curve analysis (See Figure 4.26) all CC-
RCC specimens in TA38 and TA71, split by high / low – Fuhrman Grade / 
Vessel Count (VVI). 
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Figure 4.27 – Distribution of Fuhrman Grade and VVI per number of CC-
RCC specimens within TA38 and TA71. 
 
4.2.10.3  Angiogenesis, Maximum Tumour Diameter and hypoxic 
pathway proteins 
VVI was found to negatively correlate with maximum tumour diameter 
(p=0.0210, r value -0.1992) as well as Oct-4 (p=0.0020, r value -0.2624), 
and was found to positively correlate with CAIX (p=0.0130, r value 
0.2100). (See Table 4.14) 
 
VVI    
Comparative Factor  R value  Spearman Rank 
p-value 
Maximum Tumour Diameter  -0.1992  0.0210* 
Oct-4 -0.2624  0.0020** 
CAIX 0.2100  0.0130* 
HIF-1   NS 
HIF-2   NS 
Table 4.14 – Correlations of Vessel Count (VVI) with hypoxic pathway 
proteins and macroscopic pathological tumour parameters (excluding 
Fuhrman Grade). 
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4.2.10.4Angiogenesis and HIF 
When VVI was compared to the two HIF isoforms there was no correlation 
seen, however, both HIF-1 and HIF-2 survival curves were split with VVI 
high/low. (See Figures 4.28 and 4.29). Interestingly it was low HIF-1 
tumours that was differentiated by VVI (low HIF-1 with high VVI had 
better prognosis (p=0.0004)), whilst in HIF-2 it was high HIF-2 together 
with high VVI that conferred the better prognosis (p=0.0005). Furthermore, 
both isoforms of HIF demonstrated better prognosis when high, taken 
together with high VVI, when compared to low HIF and low VVI (HIF-1 p= 
0.0054; HIF-2 p=0.0059). (See Tables 4.15 and 4.16). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by high / low –Vessel Count (VVI) / 
HIF-1 expression histoscore. 
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  HIF-
1  Angiogenesis  HIF-
1  Angiogenesis 
Logrank 
Test 
p-value 
Hazard 
Ratio (and 
95% 
Confidence 
Intervals) 
HIF-1 split by 
Angiogenesis:             
  High High vs  High Low  0.2985   
  Low High vs  Low Low 0.0004*** 
0.2786 
(0.1214-
0.5444) 
Angiogenesis 
split by HIF-
1: 
           
 High  High  vs  Low  High  0.6918  
 High  Low  vs  Low  Low  0.1229  
              
 High  High  vs  Low  Low  0.0054** 
0.3460 
(0.1681-
0.7343) 
Table 4.15 - Kaplan-Meier survival curve analysis (See Figure 4.28) all CC-
RCC specimens in TA71, split by high / low –Vessel Count (VVI) / HIF-1 
expression histoscore. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.29 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by high / low –Vessel Count (VVI) / 
HIF-2 expression histoscore. 
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  HIF-
2 
Angiogenesis  HIF-
2 
Angiogenesis Logrank 
Test 
p-value 
Hazard 
Ratio (and 
95% 
Confidence 
Intervals) 
HIF-2 split  
by 
Angiogenesis: 
           
  High High vs  High Low 0.0005***  0.2073 
(0.04821-
0.4242) 
  Low High vs  Low Low  0.1496   
Angiogenesis 
split by HIF-
2: 
           
 High  High  vs  Low  High  0.1521  
 High  Low  vs  Low  Low  0.2171  
              
 High  High  vs  Low  Low  0.0059**  0.3020 
(0.1545-
0.7297) 
Table 4.16 - Kaplan-Meier survival curve analysis (See Figure 4.29) all CC-
RCC specimens in TA71, split by high / low –Vessel Count (VVI) / HIF-2 
expression histoscore. 
 
4.2.11  VEGF in primary CC-RCC and its relationship with hypoxic 
pathway proteins, Fuhrman grade, macroscopic pathological 
tumour parameters and prognosis. 
 
4.2.11.1VEGF and Prognosis 
VEGF was not demonstrated to effect patient overall survival when using 
Kaplan –Meier survival curves. (See Figure 4.30). However, when the mean 
cytoplasmic histoscores where compared across the three time-distributed 
death cohorts, the late death cohort had significantly lower expression levels 
of VEGF compared to either early death or intermediate death (p=0.0058 
and 0.0080 respectively). (See Figure 4.31 and Table 4.17). 
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Figure 4.30 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA38 and TA71, split by high / low VEGF 
expression histoscore. 
 
 
 
 
 
 
 
 
 
Figure 4.31 - Mean VEGF expression histoscore per Time-distributed death 
cohort. 
VEGF     Mann-Whitney 
p-value 
Early Death  vs  Intermediate Death  0.3411 
Early Death  vs  Late Death  0.0058** 
Intermediate Death  vs  Late Death  0.0080** 
Table 4.17 – Mann-Whitney T-test analysis of differences between Mean 
VEGF expression histoscore per Time-distributed death cohort. 
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4.2.11.2  VEGF, macroscopic tumour markers and other Hypoxic 
Pathway Proteins including HIF 
Using Spearman Rank, VEGF was found to correlate positively with BNIP3 
(p<0.0001, r value 0.4053). No correlation was found with HIF-1, HIF-2 or 
any other measured marker of the tumour or hypoxic pathway. (See Table 
4.18). On Kaplan-Meier survival curve analysis HIF-1 or HIF-2 added no 
further prognostic significance when used to split VEGF. (See Figures 4.32 
and 4.33). 
 
VEGF    
Comparative Factor  R value  Spearman Rank 
p-value 
HIF-1   NS 
HIF-2   NS 
BNIP3 0.4053  <0.0001*** 
Table 4.18 – Correlations of VEGF with other hypoxic pathway proteins 
including HIF (non-significant comparisons not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.32 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by high / low –VEGF / HIF-1 
expression histoscore. 
VEGF, HIF-1 and Death from Kidney Cancer
0 5 10 15 20 25
0
10
20
30
40
50
60
70
80
90
100
HIF-1 High / VEGF High
HIF-1 High / VEGF Low
HIF-1 Low / VEGF High
HIF-1 Low / VEGF Low
Survival (years)
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l 
CHAPTER 4  150 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33 - Kaplan Meier Survival Curve (Death from Kidney Cancer) of 
all CC-RCC specimens in TA71, split by high / low –VEGF / HIF-2 
expression histoscore. 
 
4.2.12 Multivariate  Analysis 
When multivariate analysis was performed with a Cox proportional hazards 
test, high angiogenesis (CD31
+ VVI) was shown to be the most significant 
prognostic marker of increased overall kidney cancer specific survival. 
Additionally, a low Fuhrman grade and small tumour size (maximum 
tumour diameter) demonstrated better overall survival in primary CC-RCC. 
Neither HIF isoform nor any of their six target genes investigated here, had 
any prognostic utility. (See Table 4.19) 
 
    Variable                      Hazard Ratio                   95% CI                           p-value 
 
  CD31+ VVI                      0.3800                    0.2100-0.7012                      0.0020 
 
Fuhrman’s Grade                1.5211                    1.0413-2.2194                      0.0317 
 
  Tumour Size                     1.0885                    1.0000- 1.1735                      0.0421 
 
Table 4.19 - Multivariate analysis with a Cox proportional hazards test on 
all Clinical, Pathological, Angiogenic and Immunohistochemical analyses of 
TMAs TA38 and TA71. 
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4.3 Discussion 
4.3.1  Change in antigenicity of nuclear HIF-1 and HIF-2 over time 
It would appear that the antigenicity of HIF deteriorates with the age of the 
CC-RCC paraffin-embedded block from which the TMA core is derived. 
This phenomenon has previously been described for p53 and EGFR 
detection in human tissues (Olapade-Olaopa, Ogunbiyi et al. 2001), 
although this is the first time it has been shown for HIF isoforms.  This may 
be due to alterations in the antigenicity of the HIF molecule, possibly due to 
loss of tertiary configuration caused by the paraffin embedding process (this 
would alter the antibody affinity for cognate epitope) or degradation of HIF 
protein itself caused by paraffin embedding. 
 
If this phenomenon were true then it could cast into significant doubt 
previous literature about HIF-1 immunostaining in human cancers using this 
particular HIF-1 antibody (HIF-1α mouse monoclonal, Clone 54 BD 
Biosciences Pharmingen). Similarly, the reliability of HIF-2 
immunostaining in archival tumour samples with the antibody used within 
this study (HIF-2 mouse monoclonal, EP190, Oxford University), has also 
to be questioned.  
 
However, it is possible that the deterioration may be due to variations in the 
conditions in which the two TMAs were constructed, and therefore reflect a 
global decrease in staining efficacy in the original array. Although the 
median histoscores for HIF suggest a gradual and progressive reduction in 
HIF staining over time, the possibility of array to array variation should be 
excluded. This could be achieved by taking whole tumour sections from the 
original blocks and assessing HIF staining in them compared to age of 
specimen. Unfortunately this is beyond the scope of this thesis.  
 
 
  
CHAPTER 4  152 
 
4.3.2  HIF-1 and HIF-2 in primary CC-RCC prognosis. 
Analysis of nuclear expression of HIF-1 and HIF-2 did not demonstrate a 
correlation. This may not be reflective of the true biology, but due to the 
limited power of the analysis secondary to the unexpected loss of 93 cases 
with deterioration in their HIF antigenicity. Further work will be required 
using a larger number of cases from newer specimens to answer this 
satisfactorily, which is unfortunately beyond the scope of this thesis.   
 
Regarding the prognostic significance of either HIF isoform, it is apparent 
that neither affects overall survival in CC-RCC, and therefore this does not 
support the previous literature that HIF-1 expression has prognostic 
significance in metastatic CC-RCC (Lidgren, Hedberg et al. 2005), or that 
high HIF-2 expression confers a reduced patient survival, as has been 
demonstrated in paediatric neuroblastoma (Nilsson, Jogi et al. 2005; 
Holmquist-Mengelbier, Fredlund et al. 2006). It is possible that when both 
HIF alpha isoforms are co-expressed, as may be expected in a VHL depleted 
tumour model such as cc-RCC, the functional effects of one mitigate the 
other, possibly due to competition for HIF-1beta. However, these results 
must again be questioned due to the low numbers in the analysis secondary 
to the unexpected loss of TA38. 
 
 Furthermore, it is also worth commenting that Kaplan-Meier survival 
analysis uses cut-offs for high/low HIF expression. These were calculated in 
this case using the median histoscore; however this may not represent a 
functional difference in high / low expression of HIF. However, alternative 
cut-off values were used which also failed to reach significance. 
 
Finally, the lack of utility of both HIF isoforms as markers of disease 
prognosis within this ccRCC TMA study may be a reflection of 
experimental methodology. In breast cancer (although HIFα isoforms are 
hypoxia-induced), using whole tumour sections, diffuse expression of  
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nuclear HIF-1 seems to denote less aggressive disease with subsequent 
improved outcome on analysis (Koukourakis, Giatromanolaki et al. 2002). 
Therefore, it would be useful to perform similar experiments on matched 
CC-RCC whole tumour sections and use laser microdissection to extract 
cDNA (for HIF transcriptional products) from intra-tumoural areas that 
have differential HIF isoform expression levels. 
 
4.3.3  Time-Distributed Death Cohorts 
An alternative method of survival analysis using only patients that had died 
from CC-RCC shows clear differences in HIF-1 and HIF-2 expression 
levels between the three cohorts of early, intermediate and late tumour-
related deaths. This is particularly clear in tumours with low levels of HIF-
1, which are associated with an intermediate death group status. The 
equivalent levels of HIF-1 expression amongst the early and late death 
groups may indicate that nuclear HIF-1 interacts with different molecular 
partners in differing patient groups, which ultimately influences disease 
prognosis. However, it is possible that this finding is simply due to chance, 
and a result of the multiple analyses performed. 
 
4.3.4  HIF1 / HIF-2 and Fuhrman Grade 
Analysis of patient survival versus tumour grade demonstrates that Fuhrman 
grade 4 tumours have significantly worse prognosis in comparison to 
Fuhrman grades 1 to 3, which all have similar outcome. Differentiation 
between high and low grade was made on this result with grade 4 
determined as high grade, and grade 1-3 as low grade.  
 
Spearman rank correlation demonstrated positive correlations of grade with 
stage, maximum tumour diameter, BNIP3 and Oct-4. The relationships with 
stage and tumour size are of little surprise, given their established co-
dependence and utility as independent prognostic markers in many epithelial 
tumours. It is possible that the positive correlations with BNIP3 and Oct-4  
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may be independent of the hypoxic pathway and actually be due to genetic 
changes (such as the loss of p53) as the tumour growths and becomes less 
differentiated.  
 
Sub-division of grade by HIF-1 and HIF-2 showed no additional 
differentiation of prognosis on survival curve analysis. This is in contrast to 
a recent analysis of neuroblastomas where high HIF-2 expression could 
differentiate the low-grade tumours into distinct prognostic categories and 
overall, HIF-2 was considered a marker of neuroblastoma aggressiveness 
(Holmquist-Mengelbier, Fredlund et al. 2006). This may be reflective of the 
difference in VHL functionality between the two tumour types, such that in 
VHL sufficient tumours such as neuroblastoma, HIF-2 is induced primarily 
by hypoxia, compared to CC-RCC where it is activated mainly due to lack 
of pVHL.  
 
Multivariate analysis clearly shows tumour grade to be an independent 
prognostic marker in primary CC-RCC with high grade on either a high or 
low HIF-1 background conferring a worse survival than low grade. No 
similar effects are seen with HIF-2 possibly indicating that the biological 
factors controlling grade are superior to the effects of differential HIF-1 
signalling, although this is not the case for HIF-2 signalling. 
 
4.3.5  HIF1 / HIF-2 and Apoptosis / Autophagy 
As discussed in the introduction to this thesis, BNIP3 has been shown to be 
positively correlated with HIF-1, and negatively correlated with HIF-2 in a 
CC-RCC mouse model. In these clinical samples however, BNIP3 was not 
correlated with either HIF isoform and expression of BNIP3 had no overall 
effect on survival. This suggests that the regulation of BNIP3 is more 
complex in-vivo and may be model dependent. This could be due to the 
possible contrasting effects upon BNIP3 regulation by each HIF isoform or 
possibly that there is co-regulation of BNIP3 by binding partners such as  
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BCL-2. However, it may well be due again to the lack of cases represented 
in this analysis due to the loss of 93 cases from HIF antigen degradation. 
 
4.3.6  HIF1 / HIF-2 and pH regulation 
In-vitro experiments show that HIF-1 is the sole positive regulator of CAIX, 
but this is not recapitulated in these clinical CC-RCC samples. Whether this 
is due to the lack of samples failing to reach significance or alternative 
regulatory mechanisms of CAIX expression is unknown.  
 
4.3.7  HIF1 / HIF-2 and Proliferation 
Previous in vitro / in vivo experiments suggest that cyclin D1 is a pre-
dominant target gene of HIF, is support by this clinical series of primary 
CC-RCCs, where a strong positive correlation was demonstrate with both 
HIF-1 and HIF-2.  
 
My analysis shows that cyclin D1 has no significant influence on CC-RCC 
disease survival; however I did show that cyclin D1 expression has negative 
correlations with grade, stage and tumour size. This suggests that it may 
have a tumour suppressive role. A possible explanation of this phenomenon 
may be that high levels of cyclin D1 have a tumour suppressive effect via 
decreased proliferation rather than increased. This has certainly been the 
case in a number of epithelial tumours, including bladder and colorectal 
(Palmqvist, Stenling et al. 1998; Suwa, Takano et al. 1998), where cyclin 
D1 has been shown to have an inverse correlation with Ki-67. This may be 
due to an inhibition of glycolytic enzymes such as LDH5 as has been 
demonstrated in an inducible-cyclin D1 system in a mouse model of breast 
cancer (Yu, Geng et al. 2001). 
 
4.3.8  HIF1 / HIF-2 and Aerobic Glycolysis  
The two proteins selected to explore HIF dependent aerobic glycolysis in 
CC-RCC are located at different ends of the cell’s glucose pathways,  
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GLUT-1 (distal) and LDH5 (proximal). The in-vitro data would suggest a 
positive correlation with HIF-1; however neither HIF isoforms correlated 
with GLUT-1 or LDH5. This again may be due to the low numbers in the 
final analysis, or may reflect a general difficulty in assessing specific 
isoform correlations within a tumour where both HIF isoforms are likely to 
be ubiquitously expressed. Neither GLUT-1 nor LDH5 effected the overall 
disease survival in CC-RCC in contrast to other epithelial tumours where 
membrane expression of GLUT-1 and nuclear LDH5 have been associated 
with worse overall survival outcomes and/or higher tumour grades (Medina 
and Owen 2002; Koukourakis, Giatromanolaki et al. 2006; Colgan, 
Mukherjee et al. 2007).  
 
4.3.9  HIF1 / HIF-2 and Differentiation 
Immunohistochemical analysis of Oct-4 staining demonstrated that it was 
only differentially expressed within the cytoplasm, with constitutive 
expression within the nucleus. The cytoplasmic localization of Oct-4 within 
this study is contrary to the differential nuclear localization of Oct-4 
observed in invasive primary bladder cancer, using the same antibody 
(Atlasi, Mowla et al. 2007). This would suggest that different Oct-4 
isoforms may be expressed in different epithelial urological tumours with 
distinct oncogenic functions.  
 
Within these CC-RCC samples nuclear expression failed to correlate with 
either of the HIF isoforms, but did positively correlate with Fuhrman grade. 
The failure of Oct-4 to correlate with HIF-2 goes against strong in-vitro data 
suggesting HIF-2 specific binding to Oct-4’s promoter region. However this 
may be related to the difference in cellular localisation as previously 
discussed. The correlation with grade may be explained by Oct-4 having a 
putative role as a growth factor signalling protein and indeed this function 
has been proposed for cytoplasmic Oct-4 before (Covello, Kehler et al. 
2006).   
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4.3.10  HIF1 / HIF-2 and Angiogenesis 
The regulation of angiogenesis within primary human CC-RCC is highly 
complex. This is highlighted by the fact that the methodology of vessel 
quantification has been shown previously to change the prognostic value of 
angiogenesis (Sabo, Boltenko et al. 2001; Fox and Harris 2004; Yao, Qian 
et al. 2007). This is also the case in this analysis where the chosen method 
of CD31
+ vessel quantification, VVI, did not correlate with either HIF 
isoform or VEGF. Furthermore, neither HIF-1 nor HIF-2 correlated to 
VEGF expression. 
 
Interestingly, there is a strong positive correlation between VEGF and 
cytoplasmic BNIP3. Both proteins can be positively regulated by HIF-1 in 
vitro, although this was not recapitulated in vivo within this clinical series. 
As well, in vitro experiments have shown that they share marked similarities 
in transcriptional regulation (HIF-induced or otherwise), as well as 
similarities in protein stability – poorly stable with high affinities for 
proteosomal degradation (Guo, Searfoss et al. 2001). Therefore, it is 
possible that the positive correlation between VEGF and BNIP3 may reflect 
their overlapping regulatory mechanisms at a transcriptional level.  
 
Differential levels of angiogenesis, as measured by the CD31
+ VVI, had a 
marked effect on overall disease survival in primary CC-RCC, as well as 
demonstrating an effect within the patients who died of CC-RCC. High 
levels of CD31
+ VVI conferred a better overall disease prognosis when 
compared to low CD31
+ VVI and higher levels were also expressed within 
the late death cohort patients when compared to their early death 
counterparts. There was a strong negative correlation between VVI and 
tumour grade, and this, together with the fact that high VVI conferred a 
better prognosis than low VVI in the low-grade tumours, underlies the 
utility of the VVI as a prognostic marker within low-grade CC-RCC.  
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Additionally, it demonstrates that a high VVI cannot rescue patients with 
high-grade tumours from their worse prognostic fate. Indeed, the CD31
+ 
VVI was confirmed as the most powerful independent prognostic factor on 
multivariate analysis. 
 
At first appearance, a high VVI conferring a better overall survival may 
seem counterintuitive, but the functionality of angiogenesis may be 
determinant here. Given that CD31
+ endothelial cells may represent either 
undifferentiated or differentiated endothelium, it is possible that the CD31
+ 
vessels identified within this study are functional, such that a high VVI is 
related to good tumour microcirculation and ultimately better tumour 
perfusion. This would enable enhanced removal of aerobic glycolysis end-
products, such as lactate and H
+. Cancer cells within these high VVI 
tumours are probably not exposed to sustained periods of ischaemia, unlike 
the low VVI group, from which hypoxia death-resistant clones could arise 
facilitating tumour metastasis. 
 
Furthermore, it is possible that high CD31+ angiogenesis represents ordered 
new vessels growth, resembling normal tissue. Low CD31+ VVI may 
therefore represent disorganised angiogenesis, itself a reflection of many 
angiogenic tumour stimuli and pathways. It maybe that it is this difference 
in angiogenic stimulation that truly represents the discrepancy in patient 
outcome seen. 
 
As Fuhrman tumour grade increases, the degree of angiogenesis decreases. 
Mechanistically, it could be proposed that a reduction in angiogenesis with 
subsequent increase in tumour ischaemia / hypoxia drives morphological de-
differentiation. This may, in turn, drive an increase in tumour proliferation, 
(as demonstrated by the negative correlation between tumour size and the 
VVI). Sustained ischaemia could subsequently select for cancer cells that  
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have comparatively lower levels of cyclin D1, facilitating tumour 
proliferation.  
 
As regards the lack of any relationship between each HIF isoform and 
angiogenesis, this may not be too surprising given that both HIF isoforms 
are constitutively expressed in CC-RCC as opposed to other solid tumours. 
Indeed, the literature that has shown positive correlation between HIF-2 and 
angiogenesis is in tumours where HIF expression is induced via hypoxia, 
such as neuroblastoma and teratoma (Covello, Simon et al. 2005; Covello, 
Kehler et al. 2006; Holmquist-Mengelbier, Fredlund et al. 2006), as opposed 
to VHL deficiency.  
 
Recent literature also suggests a differential role of CD31 and CD34 in 
endothelial cell function, such that CD34
+ endothelium is thought to be 
mature and CD31
+ CD34
- endothelium is immature with poor functionality, 
as manifest by poor pericyte coverage (identified by -SMA staining). 
Therefore, it would be prudent to co-label the TMAs or whole tumour 
sections with CD31 and -SMA (+/- CD34), using double (or triple) 
labelling immunofluroscence confocal microscopy.  It would be 
hypothesised that if the CD31 vessels identified in this CC-RCC TMA study 
are indeed functional, they are more likely to co-express -SMA and CD34. 
 
The finding of high CD31
+ VVI being indicative of better overall survival in 
primary CC-RCC does potentially highlight one problem as regards anti-
angiogenic therapies. Novel agents such as bevacuizmab and sorafanib are 
potential candidates for both neo-adjuvant (pre-nephrectomy) and adjuvant 
(post-nephrectomy) therapies in primary CC-RCC. However, one would 
also need to ascertain whether the angiogenesis within the primary tumour 
was functional or not, as this data implies that if CD31 angiogenesis were 
reduced by such drugs, patient survival may be detrimentally affected. 
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Indeed, the success of both bevacuzimab and tyrosine kinase inhibitors 
sorafanib or sutinib in Phase II/III clinical trials in metastatic CC-RCC may 
indicate that the angiogenic phenotype changes with disease progression. In 
primary CC-RCC, given this data, the vasculature is mature due to 
endothelial differentiation, but within metastatic tumour sites, the 
endothelium is poorly functional and subsequently immature. Therefore, a 
comparative serial study of primary verses secondary CC-RCC, for analysis 
of the angiogenic functional phenotype, may highlight important 
differences.  
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Chapter 5:  MicroRNA in Clear Cell Renal Carcinoma and its 
relationship with VHL 
 
5.1  Introduction 
MicroRNAs are a recently discovered novel class of gene regulators, some 
of which have been shown to interact with known oncogenic or tumour-
suppressor pathways. Nine microRNAs are expressed in hypoxic conditions 
under HIF-1 induction (MiR 23, 24, 26, 27, 103, 107, 181, 210 and 213) 
(See Table 1.4); however the expression of microRNA in CC-RCC, a cancer 
with known reliance on the hypoxia / HIF axis, and its relationship with 
VHL functionality are yet to be explored.  
 
5.2  Results 
5.2.1  MicroRNA isolation 
As described in the Materials and Methods section of this thesis, MicroRNA 
was purified from total RNA from these cell lines. Analysis of size within 
the differing portions of RNA, using a 2100 Bioanalyser (Agilent, UK), 
allowed assessment of sample quality. 
 
Three samples were run in parallel: total RNA, total RNA excluding 
microRNA and purified microRNA. Figure 5.1 demonstrates a typical 
example of the quality of samples attained from microRNA purification. 
The three overlapping curves show total unpurified RNA (green); filtered 
RNA with microRNA extracted (red); and purified microRNA (blue). This 
typical graph represents good quality starting RNA with only small RNA 
(i.e. microRNA) contained within the purified fraction. 
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Figure 5.1 – Graph generated from Bioanalyser (Agilent, UK) showing 
MicroRNA isolation. Three samples run in parallel (total RNA, total RNA 
excluding microRNA and purified microRNA), from 768-0/VHL+ve cell 
line. 
 
 
5.2.2  MicroRNA MicroArrays 
5.2.2.1   Quality control 
As stated in Chapter 2 of this thesis (Materials and Methods) subjective 
assessment of array quality was made after scanning, with only high quality 
arrays being included in the analysis. (See Figure 2.6). Microarrays were 
repeated as necessary to complete three biological replicates per cell line 
comparison. 
 
Non-specific binding of the Cy3 or Cy5 dyes was excluded computationally 
by comparing nucleotide sequences of the Cy tags to the known sequences 
 
 
TotalRNA prior to purification 
MicroRNA 
Total RNA without MicroRNA  
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of the microRNAs. Furthermore, two additional microarrays were 
performed on identical samples. This showed no difference in hybridisation 
between Cy3 and Cy5 tagged cDNA.  
 
5.2.2.2   Graphical representation of data 
All graphical data below represents a change in the VHL mutated cells 
(VHL-ve) over the VHL functional cell (VHL+ve). This corresponds to a 
fold change of microRNA expression in the VHL mutated cells, compared 
to microRNA expression in the VHL functional cells. For consistency, the 
hypoxic experimental data is also represented in a fold change of hypoxia 
over normoxia. 
 
5.2.2.3   VHL+ve vs. VHL-ve  
MicroRNA expression microarrays were performed for each cell line, 
comparing differential microRNA expression between the VHL mutated 
cells (VHL-ve) and the VHL functional cells (VHL+ve). Within each 
microarray, individual microRNAs were replicated 4 times, and each array 
was repeated three times in biological triplicate, giving a total of 12 
replicates per microRNA per cell line. (See Table 5.1). 
 
Differential expression of microRNAs was assessed by comparison of 
microRNA expression across all cell lines in VHL-ve / VHL+ve 
experiments. Figure 5.2 demonstrates the considerable variability between 
the expression of different microRNAs between cell lines, with many being 
up or down regulated, as well as those with no differential expression.   
 
To focus the results and improve the reliability of the data, only those 
microRNAs that were expressed in all three replicates, in all three cell lines 
were included. (See Figure 5.3). This demonstrates that five microRNAs are 
robustly expressed in CC-RCC cell lines: miR-23a, miR-15b, miR-103, 
miR-24 and miR-21.  
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To further investigate which of these microRNAs are reliably differentially 
regulated by the presence of a functional VHL gene, only those microRNAs 
that had differential expression in all three of the cell lines was included. 
The cut-off criterion for significant differential expression was taken as a 
fold change of 1.35. (See Figure 5.4). These strict inclusion criteria 
narrowed the results to highlight only one microRNA, miR-23a that was 
reliably differentially expressed. 
 
Cell Type  Paired Variable 
768-0  768-0/VHL+ve vs. 768-0/VHL-ve 
RCC4  768-0/VHL+ve vs. 768-0/VHL-ve 
UMRC2  768-0/VHL+ve vs. 768-0/VHL-ve 
7680/VHL+ve  Normoxia (21% O2) vs. Hypoxia (0.1% O2) 
RCC4/VHL+ve  Normoxia (21% O2) vs. Hypoxia (0.1% O2) 
UMRC2/VHL+ve  Normoxia (21% O2) vs. Hypoxia (0.1% O2) 
Table 5.1 – Paired variables per cell line for MicroRNA expression 
microarrays. All performed in biological triplicate.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 - VHL-ve / VHL+ve: All microRNAs expressed in the three cell 
lines (768-0 (left); RCC4 (centre); and UMRC2 (right)), represented as 
expression of all microRNAs median fold change (relative to VHL-ve) with 
error bars, across the three cell lines.  
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Figure 5.3 - VHL-ve / VHL+ve: All microRNAs expressed in all three 
biological replicates, in all three cell lines, represented as expression of all 
microRNAs median fold change (relative to VHL-ve) with error bars, across 
the three cell lines. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 - VHL-ve / VHL+ve: All differentially expressed microRNAs in 
all three biological replicates, in all three cell lines, represented as 
expression of all microRNAs median fold change (relative to VHL-ve) with 
error bars. 
miR-23a 
miR-15b 
miR-103 
miR-24 
miR-21 
miR-23a  
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5.2.2.4   Hypoxia vs. Normoxia (VHL+ve)  
To validate that the observed differentially expressed microRNAs were 
specific to the HIF / hypoxia axis, further microarrays were performed on 
the VHL functional cells (VHL+ve) after exposure to 16 hours of normoxia 
(21% O2) versus hypoxia (0.1% O2). No expression arrays were performed 
for VHL mutated cell (VHL-ve) in normoxia versus hypoxia as no 
differentiation hypoxia induced expression would be expected, due to the 
constitutive expression of HIF in VHL-ve cells (Maxwell, Wiesener et al. 
1999). As with the previous experiments (VHL-ve vs. VHL+ve), microRNA 
expression microarrays were performed for each cell line, in biological 
triplicate. Differential microRNA expression was assessed between the 
VHL functional cell, cultured in hypoxic conditions and the same cells 
cultured in normoxia. As before, within each microarray, individual 
microRNAs were replicated 4 times, resulting in a total of 12 replicates per 
microRNA per paired cell line. (See Table 5.1). 
 
All microRNAs expressed in the first batch of arrays (VHL-ve / VHL+ve) 
were cross-referenced with the results from this second set of microRNA 
microarrays (VHL+ve Hypoxia vs. VHL+ve Normoxia). Figure 6.5 shows 
that all of the five ubiquitously expressed microRNAs identified in the first 
batch of arrays were also expressed in the VHL functional cells exposed to 
normoxia and hypoxia. Furthermore, the only microRNA that was 
differentially expressed in all these arrays was miR-23a. (See Figure 5.6). 
 
5.2.2.5   MicroRNA 23a expression in MicroRNA microarrays 
MicroRNA 23a was therefore identified to be differentially expressed in all 
cell lines. The direction of regulation was consistent with the hypoxic 
pathway, as upregulation was seen in VHL mutated cells compared to VHL 
functional cells, and in VHL functional cells subjected to hypoxia compared 
to the same cells cultured in normoxia. (See Figure 5.7). 
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Figure 5.5 - VHL+ve Hypoxia vs. Normoxia: All five ubiquitously 
expressed microRNAs from first batch of arrays (VHL-ve / VHL+ve), 
expressed in all three biological replicates, in all three cell lines (VHL+ve 
Hypoxia / Normoxia). Represented as expression of all microRNAs median 
fold change (relative to VHL+ve Hypoxia) with error bars. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 - VHL+ve Hypoxia vs. Normoxia: All differentially expressed 
(fold change >1.35) microRNAs in all three biological replicates, in all three 
miR-23a 
miR-23a 
miR-15b 
miR-103 
miR-24 
miR-21  
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MicroR N A  23a Fold Change - MicroA rray Data
N o n - F u n ct i o n   VH L   o r   H yp o xi a  /   F u n ct i o n al   VH L   o r   N o r mo xi a
7
6
8
0
 
V
H
L
 
-
/
+
7
6
8
0
 
H
y
p
/
N
o
r
m
R
C
C
4
 
V
H
L
 
-
/
+
R
C
C
4
 
H
y
p
/
N
o
r
m
U
M
R
C
2
 
V
H
L
 
-
/
+
U
M
R
C
2
 
H
y
p
/
N
o
r
m 0 . 0
0 . 5
1 . 0
1 . 5
2 . 0
2 . 5
3 . 0
3 . 5
4 . 0
4 . 5
F
o
l
d
 
 
C
h
a
n
g
e
cell lines (VHL+ve Hypoxia / Normoxia). Represented as expression of 
microRNA median fold change (relative to VHL+ve Hypoxia) with error 
bars. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 – Summary of differential expression of microRNA 23a across 
all microarray experiments. Represented as fold change of VHL-ve or 
VHL+ve Hypoxia over VHL+ve or VHL+ve Normoxia. 
 
5.2.3  Quantitative Real-Time Polymerase Chain Reaction (PCR) 
Validation 
Validation of the expression of miR-23a was investigated by qRT-PCR, 
(RT-PCR assay kit (Taqman, Applied Biosystems)). The small ribosomal 
RNA, RNU6B was used as an internal control, as its expression is consistent 
across cell lines (Lawrie, Soneji et al. 2007). 
 
As described in detail in the materials and methods section of this thesis, 
5ng of total RNA was probed with miR-23a and RNU6B, and cycled on a 
Roche LightCycler 480. Biological triplicate samples were used throughout. 
 
MicroRNA 23a was found to be expressed in all the cell lines. Figure 5.8 
and Table 5.2 show its differential expression across all paired cell lines.  
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MicroRNA 23a in CC-RCC Cell Lines
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The results are consistent with the microarray data for the RCC4 and 
UMRC2 cell lines, with microRNA-23a confirmed as being upregulated in 
VHL mutated cells and VHL +ve hypoxic cells. However there was a 
reversed trend for the 768-0 cells, where microRNA-23awas found to be 
down regulated. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 – qRT-PCR median expression levels of microRNA 23a 
represented as fold-change (relative to mutated VHL (VHL-ve) or VHL+ve 
hypoxia). 
 
Cell Line  Variable  Median Fold Change  Fold Change 
Range  P value (t-test) 
768-0  VHL-ve / 
VHL+ve  -1.7  -1.5 - -1.8  0.0001 
RCC4  VHL-ve / 
VHL+ve  4.6  3.1 – 9.1  0.027 
UMRC2  VHL-ve / 
VHL+ve  2.4  1.3 – 3.6  0.027 
768-0  Hypoxia / 
Normoxia  -1.7  -1.1 - -1.8  0.021 
RCC4  Hypoxia / 
Normoxia  1.3  1.3 – 1.6  0.0060 
UMRC2  Hypoxia / 
Normoxia  2.0  1.5 – 2.2  0.010 
 
Table 5.2 - Median expression levels of MicroRNA 23a represented as fold-
change (relative to mutated VHL or VHL+ve hypoxia).  
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5.3  Discussion 
5.3.1  Optimisation 
Significant optimisation of the available methodology was required to 
achieve the results presented in this chapter. This was primarily because 
isolation of microRNA and its subsequent hybridisation had not previously 
been performed on cell line samples at the commencement of this research, 
within the institution where it was performed. Following this work many 
more microRNA experiments have been performed at this institution, and 
the optimised protocols as described in Chapter 2 of this thesis, have 
allowed improved quality and efficiency of results. 
 
5.3.2  MicroRNA Isolation 
The isolation of microRNA from total RNA is a vital first step in the 
generation of microRNA microarrays. The commercially available 
microRNA separation kits rely upon size discrepancies between standard 
RNA and microRNA. The generation of good quality (i.e. unfragmented) 
total RNA from the cell line cultures results in a high percentage of 
microRNA within the small RNA fraction. This subsequently decreases 
non-specific binding of RNA fragments to the microarray, together with 
increasing the actual quantity of microRNA used for the experiment. Figure 
5.1 demonstrates the quality of total RNA used in a typical experiment and 
highlights the minimal total RNA fragmentation within these experiments. 
 
5.3.3  MicroArrays 
It became clear during the analysis of my arrays that there was a reasonable 
amount of variability in the number of microRNAs expressed in different 
cells lines, and also between different experiments on the same cell line. 
This is an inherent problem due to the complex methodology of microarray 
hybridisation. Every effort was made to improve this sensitivity by 
optimising the methodology, and by having a low threshold for repeating 
the microarray if the sensitivity was poor. However, it is clear from the  
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results that not all microRNA expression is demonstrated using these 
methods. Furthermore, there may well be functional microRNAs that are yet 
to be discovered and are therefore not represented in these arrays.  
 
However, although my arrays may have failed to produce a complete list of 
all expressed microRNAs in these cells, the low sensitivity improves the 
confidence that the microRNAs that were highlighted are reliably expressed.  
 
Reliability in results was further improved by strict inclusion criteria, with 
only microRNAs expressed in all three biological replicates, across all three 
cell lines, included in analysis. This stringent method of exclusion may well 
have ignored many microRNAs that could be functionally important; 
however, I felt that the robustness of the results was of greater importance 
than quantity. Therefore, the completeness of microRNA expression in CC-
RCC may not be answered by these results, but it is my hope that the most 
important individual microRNAs have been highlighted. 
 
5.3.4  RT-PCR 
RT-PCR is established as a more accurate measure of expression, compared 
to microarray analysis. I was unable to validate all of my results by this 
method, only the microRNA that was highlighted as the most interesting, 
miR-23a. Validation of the others (miR-15b, miR-103, miR-24 and miR-21) 
would be of value and interest in the future.   
 
MiR-23a was highlighted as the only robustly expressed microRNA in CC-
RCC, which was consistently differentially regulated. The RT-PCR 
confirmed the microarrays in proving that miR-23a is expressed in all the 
cell lines; however the direction of regulation was different in 768-0 when 
compared to the arrays. It did confirm a significant up-regulation in RCC4 
and UMRC2 cell lines.  
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Assuming the PCR data to be the true reflection of the biology, it is possible 
that the differential expression of miR-23a is reflective more of the 
dominant HIF isoforms expressed. 768-0 does not express HIF-1alpha, only 
HIF-2alpha, whilst the other two cells express both HIF isoforms. Therefore 
it is possible that HIF-1 and HIF-2 have a reciprocal effect on miR-23a 
expression. Dependent upon the potential targets of miR-23a this may 
induce pro-tumourigenic or anti-tumourigenic effects, in keeping with the 
hypothesis from chapter 4 of this thesis, and the results of Raval et al. 
(Raval, Lau et al. 2005). 
 
5.3.5  MicroRNA 23a 
5.3.5.1   Background 
MicroRNA 23a (AUCACAUUGCCAGGGAUUUCC ) is a 21 nucleotide 
microRNA that was first identified in 2001 (Lagos-Quintana, Rauhut et al. 
2001). It is highly conserved (expressed in human, rhesus monkey, mouse, 
dog, horse, platypus, lizard and chicken) (University of California Santa 
Cruz - Genome BioInformatics). Kawasaki and Taira reported that miR-23 
regulates the transcriptional repressor Hairy enhancer of split (HES1) 
(Kawasaki and Taira 2003). However, this finding was later retracted after 
the discovery that the regulated gene was human homolog of ES1 (HES1), 
whose function is unknown.  
 
5.3.5.2   Potential Targets 
MiRBase (Sanger Institute (Olapade-Olaopa, Ogunbiyi et al. 2001; 
miRBase Database)) highlights 1227 potential targets for miR-23a. Ranked 
according probability of regulation (via miRBase algorithm), Lactate 
Dehydrogenase-B (LDH-B) is registered as 25
th on the list, with a p-value of 
0.000006.  
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5.3.5.3   Lactate Dehydrogenase (LDH) 
LDH catalyses interconversion of lactate to pyruvate. Two genes LDH-A 
and LDH-B encode five LDH isoenzymes, each with variability of 
localisation within different human viscera and differential effects on 
regulation of aerobic glycolysis. LDH-A is a known target of HIF-1, and has 
greater efficiency in aerobic glycolysis in hypoxic conditions (Koukourakis, 
Giatromanolaki et al. 2005). Loss of LDH-B expression will lead to greater 
LDH-A expression and increased malignant potential of cells (Leiblich, 
Cross et al. 2006). LDH-B has been shown to be repressed by hypoxia in 
CC-RCC cells (Maxwell, Wiesener et al. 1999) and its promoter has been 
shown to be hypermethylated in prostate cancer (Leiblich, Cross et al. 
2006). 
 
LDH-B is a potentially interesting target for miR-23a as it is repressed by 
hypoxia compared to LDH-A, a HIF-1 target. It may be possible that the 
expression level of miR-23a is reflective of LDH-B or inhibits it? Therefore, 
in a hypoxic tumour environment LDH-A is upregulated by HIF-1 binding 
to its HRE, whilst LDH-B is repressed by an interaction with miR-23a. This 
would give the tumour cell greater aerobic glycolytic efficiency and 
encourage tumour cell survival.  
 
This differential expression in tumour cells that express either HIF-2 only or 
both HIF isoforms suggests that miR-23a’s function is likely to be regulated 
by HIF rather than interacting directly with pVHL in CC-RCC.    
 
5.3.6  Future Work 
Differential protein expression levels of LDH-A and LDH-B within these 
cell lines in normoxia and hypoxia would be of value in examining the 
interaction between hypoxia, HIF, miR-23a and LDH. Furthermore it would 
be of great interest to explore the expression patterns of miR-23a in cells 
that have had either HIF-1 or HIF-2 knocked down, as well as the change in  
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gene expression if miR-23a was knocked down or over expressed. I believe 
it is the plan for my research successors in my institution to explore these, 
and hopefully the function and true significance of miR-23a will be 
elucidated in CC-RCC. 
 
  
 
 
 
 
 
 
 
 
 
 
Chapter 6: 
Final Discussion and Conclusions  
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Chapter 6:  Final Discussion and Conclusions 
 
6.1  Final Discussion 
The analysis of all the RCC nephrectomies from Oxford (1983-2007) in this 
thesis has clearly demonstrated that patient survival has dramatically 
improved over this time period. The most important driving influences 
behind this trend appear to be the decrease in tumour size at time of 
operation, and the number of operations performed. This would certainly fit 
with the increased quality and quantity of diagnostic imaging, and the 
greater number of incidental (pre-symptomatic) tumours that are being 
detected worldwide (Chow, Devesa et al. 1999). Detection of renal tumours 
whilst they are locally confined and amenable to curative nephrectomy, 
clearly affords the patient a survival benefit. 
 
Further to this, analysis of Fuhrman grade within these tumours has shown 
that 5-year survival has significantly improved from grade 1 and 2 tumours, 
yet survival of grade 3 and 4 tumours is unchanged (See figures 3.8 and 
3.9). Additionally, analysis of maximum tumour diameter at nephrectomy 
demonstrated a stable incidence rates of tumours >8cm, whilst tumours 
<8cm have a shift in their distribution towards smaller maximal diameters. 
Taken together this suggests that although there has been increased 
detection of tumours of a smaller size, there has also been a change in the 
biology of these tumours. It is possible that Fuhrman grade increases as the 
tumour grows, which again may be due to changes in the molecular 
pathways of the tumour as a response to hypoxia or other stimuli. 
Alternatively the increased detection of renal tumours by imaging may be 
causing Urological Surgeons to remove renal tumours that may not have 
proved clinically significant to the patient. However, without further 
understanding of the different molecular pathways and natural clinical 
courses in these two possible alternative renal tumours, it is impossible to  
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withhold known curative treatment, for patients diagnosed with a renal 
tumour by imaging.  
 
Although this thesis has failed to identify clear correlations between the HIF 
isoforms or the primary hypoxic target genes (except cyclinD1) is has 
successfully managed to highlight many other interesting areas.  
 
This thesis has clearly demonstrated that the antigenicity of HIF does 
deteriorate with the age of the paraffin-embedded block from which the 
TMA core is derived. Although this phenomenon has previously been 
described it is the first time it has been shown for HIF isoforms, and is a 
very important finding since it casts into significant doubt previous 
literature about HIF-1 and HIF-2 immunostaining in human cancers using 
these particular antibodies.  
 
The subsequent lack of significance of the HIF isoforms with each other or 
their target genes is surely related to the loss of over 50% of the clinical 
samples in this series. However it would have been incorrect to include 
known erroneous data into the analysis. Further work will be required 
assessing the relationship of the HIF isoforms in ccRCC, with larger 
numbers of samples from fresher specimens, although unfortunately this 
would extend beyond the scope of this thesis.  
 
An additional factor is the methodology used to assess this HIF isoforms in 
these tumours. TMAs have certainly allowed a large number of tumours to 
be assessed together, adding statistical weight to the correlations shown in 
this thesis. The real situation however may be more complex within the 
tumour as a whole. The TMA cores have only sampled a representative 
histological area; however the remaining tumour may be significantly 
different when pertaining to dominant HIF isoform staining. Further work 
on these TMAs is currently being conducted to examine HIF-1 and HIF-2  
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within the whole tumour section. Correlation between HIF staining on the 
TMAs and whole sections will be important to ascertain whether this is truly 
significant. 
   
Further work in this thesis has demonstrated that differential levels of 
angiogenesis, as measured by the CD31
+ VVI, have a significant prognostic 
value in ccRCC. High levels of CD31
+ VVI conferred a better overall 
disease prognosis when compared to low CD31
+ VVI and higher levels were 
also expressed within the late death cohort patients when compared to their 
early death counterparts.  
 
Although at first appearance, a high VVI conferring a better overall survival 
seems counterintuitive, it may be that CD31
+ endothelial cells represent 
either undifferentiated or differentiated endothelium, and the CD31
+ vessels 
identified in this thesis are functional. This may mean that a high VVI is 
related to good tumour microcirculation and ultimately better tumour 
perfusion. This would enable reduction in sustained periods of ischaemia, 
unlike the low VVI group, from which hypoxia death-resistant clones could 
arise facilitating tumour metastasis. 
 
Furthermore, it is possible that high CD31+ angiogenesis represents ordered 
new vessels growth, resembling normal tissue. Low CD31+ VVI may 
therefore represent disorganised angiogenesis, itself a reflection of many 
angiogenic tumour stimuli and pathways. It maybe that it is this difference 
in angiogenic stimulation that truly represents the discrepancy in patient 
outcome seen. 
 
Additionally, the negative correlation of angiogenesis (CD31+) to Fuhrman 
grade and tumour size suggests that hypoxic pathway changes as a tumour 
increases in size. Although no specific correlations to HIF have been 
identified in this thesis, it may be that tumours >8cm have alterations in  
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their angiogenic pathways leading to a poorly differentiated and aggressive 
phenotype. 
 
The finding of high CD31
+ VVI being indicative of better overall survival in 
primary CC-RCC does potentially highlight one problem as regards anti-
angiogenic therapies. Novel agents such as bevacuizmab and sorafanib are 
potential candidates for both neo-adjuvant (pre-nephrectomy) and adjuvant 
(post-nephrectomy) therapies in primary CC-RCC. However, one would 
also need to ascertain whether the angiogenesis within the primary tumour 
was functional or not, as this data implies that if CD31
+angiogenesis were 
reduced by such drugs, patient survival may be detrimentally affected. 
 
Due to the complex nature of microRNA microarrays a complete pattern of 
microRNA expression has been impossible to demonstrate. However the 
emergence of microRNA 23a from the array data, and its subsequent 
validation via PCR has highlighted an interesting target for further study. 
This is particularly the case due to the possible differential effect of HIF-1 
and HIF-2 expression of miR-23a.  
 
Target prediction remains a difficult problem within the microRNA field, 
with many thousands of targets commonly predicted by the best available 
algorithms. Functional studies will eventually overcome this difficulty, but 
it will take time for these results to emerge. MicroRNA-23a is currently 
under further investigation within the institution where this work was 
performed, and hopefully its role in the hypoxic pathway will become clear 
in the near future. 
 
6.2  Conclusion 
In conclusion, this thesis has shown kidney cancer to be an aggressive and 
lethal condition that is becoming increasingly prevalent. Our current 
management is working well with patient prognosis increasing; however, it  
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is through the further understanding of the biological nature of the disease 
that we will be able to develop novel treatments targeted against it. This will 
undoubtedly be to the benefit of patients, and I hope that the work contained 
within this thesis has brought that closer.  
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